Modified virus targeting tumors associated with aberrant PAX family transcription factors
By designing modified viruses containing cis-acting elements that bind to PAX family transcription factors and target genes, the specificity and safety issues of killing tumor cells abnormally associated with PAX family transcription factors in existing technologies have been solved, achieving efficient killing of tumor cells and safe treatment.
Patent Information
- Application Number
- PCT/CN2026/093521
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-04-28
- Publication Date
- 2026-11-12
AI Technical Summary
Existing technologies struggle to achieve highly specific killing of tumor cells associated with abnormal PAX family transcription factors, and traditional treatment methods have safety and side effects issues.
A modified virus was designed containing a cis-acting element capable of binding to PAX family transcription factors and an operable target gene. The virus activates downstream protein expression when it recognizes an abnormal PAX family transcription factor, promoting explosive viral proliferation and killing cancer cells, or achieving tumor-specific killing by regulating the expression of suicide genes.
It achieves highly specific killing of tumor cells, has high safety, and has broad application potential. It also achieves specific killing of cells through the regulation of suicide genes.
Smart Images

Figure PCTCN2026093521-FTAPPB-I100001 
Figure PCTCN2026093521-FTAPPB-I100002 
Figure PCTCN2026093521-FTAPPB-I100003
Abstract
Description
Modified viruses targeting tumors associated with abnormalities in PAX family transcription factors Technical Field
[0001] This application relates to the field of biomedicine, specifically to a modified virus. Background Technology
[0002] The PAX (Paired box) transcription factor family is a class of transcription factors containing paired box DNA-binding domains, which play a crucial role in embryonic development, cell differentiation, and tissue formation. PAX family members regulate the expression of downstream genes by binding to specific DNA sequences, and they play important roles in organogenesis, neural development, hematopoiesis, and the maturation of the immune system.
[0003] Aberrant expression of PAX transcription factors is associated with a variety of diseases. For example, aberrant expression of PAX transcription factors in tumor cells is associated with the development and progression of various cancers. Targeting PAX transcription factors or the gene network they regulate may provide new strategies for disease treatment. Summary of the Invention
[0004] This application provides a cis-acting element for fusion proteins containing PAX family transcription factors, which has high specificity and activates the regulation of target gene expression only in cells containing fusion proteins containing PAX family transcription factors, while the target gene is not expressed or is expressed at low levels in normal cells. It has high safety and few side effects, thereby achieving tumor specificity.
[0005] Furthermore, this application also provides a modified virus containing the aforementioned cis-acting element. On one hand, the virus's tumor-killing ability can be utilized by placing a gene essential for viral replication after the cis-acting element described in this application. Upon recognition of abnormal PAX family transcription factors, downstream protein expression is activated, promoting explosive viral proliferation, killing cancer cells, and achieving oncolysis. The modified virus provided in this application not only possesses highly specific replication ability in tumor cells and exhibits excellent killing effects on tumor cells, but also can target and kill multiple types of tumor cells. Its effectiveness is significant, its safety is high, and it has broad application potential. On the other hand, the cis-acting element described in this application can also regulate the expression of target genes with anti-tumor effects. For example, the cis-acting element described in this application can regulate the expression of suicide genes, thereby regulating the expression of suicide genes in cells with abnormal PAX family transcription factors, thus achieving a specific killing effect on cells.
[0006] On one hand, this application provides a modified virus having a cis-acting element in the 5' to 3' direction capable of binding to a fusion protein containing a PAX family transcription factor and a target gene operatively linked to the cis-acting element, wherein the cis-acting element contains a domain that binds to a PAX family transcription factor, and the domain that binds to a PAX family transcription factor contains the nucleotide sequence shown in SEQ ID NO: 1.
[0007] In some embodiments, the domain that binds to PAX family transcription factors is capable of binding to the DNA-binding domain of PAX family transcription factors.
[0008] In some implementations, the cis-acting element includes a promoter and / or an enhancer.
[0009] In some embodiments, the cis-acting element is a promoter that includes a domain that binds to PAX family transcription factors and a minimal promoter.
[0010] In some embodiments, the minimal promoter is located at the 3' end of the PAX family transcription factor binding domain.
[0011] In some implementations, the minimum promoter includes at least one TATA box element.
[0012] In some implementations, the minimum promoter includes the minimum CMV promoter.
[0013] In some embodiments, the minimal promoter comprises the nucleotide sequence shown in SEQ ID NO: 6.
[0014] In some embodiments, the domain that binds to PAX family transcription factors comprises the nucleotide sequence shown in any one of SEQ ID NO: 2-5.
[0015] In some embodiments, the cis-acting element comprises a nucleotide sequence shown in any one of SEQ ID NO: 7-10.
[0016] In some embodiments, the fusion protein containing PAX family transcription factors includes PAX3-FOXO1, PAX7-FOXO1, PAX3-MAML3, PAX3-NOCA1, PAX3-NOCA2, PAX5-ETV6, PAX5-ELN, PAX7-PPARGC1A, PAX8-GLIS3, and PAX8-PPARG.
[0017] In some embodiments, the target gene includes a gene essential for viral replication.
[0018] In some embodiments, the expression and / or activity of the at least one gene essential for viral replication is downregulated in the modified virus, so that the virus does not have the ability to self-replicate in cells or tissues in which PAX family transcription factors are normally expressed, and only self-replicates and proliferates in cells or tissues containing fusion proteins comprising PAX family transcription factors.
[0019] In some embodiments, the at least one gene essential for viral replication is downregulated by gene editing and / or gene recombination.
[0020] In some embodiments, the gene editing includes the use of antisense RNA, siRNA, shRNA, and / or CRISPR / Cas systems.
[0021] In some embodiments, when the virus is an adenovirus, the target gene is selected from one or more genes essential for viral replication from the group consisting of: early protein 1A, early protein 1B19K, early protein 1B55K, capsid protein Iva2, DNA polymerase, terminal protein precursor pTP, capsid protein 52K, capsid protein precursor pIIIa, pentazoc matrix, core protein pVII, core protein precursor pX, core protein precursor pVI, hexazoc, protease, single-stranded DNA-binding protein, hexamer assembly protein 100K, protein 33K, capsid protein 22K, capsid protein precursor, protein U, fibrin, regulatory protein E4 open reading frame 6 / 7, regulatory protein E4 34K, regulatory protein E4 open reading frame 4, regulatory protein E4 open reading frame 3, regulatory protein E4 open reading frame 2, and regulatory protein E4 open reading frame 1.
[0022] In some embodiments, the target gene comprises the early protein 1A gene.
[0023] In some embodiments, the target gene comprises the nucleotide sequence shown in SEQ ID NO: 14 or the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 13.
[0024] In some embodiments, the target gene includes a suicide gene.
[0025] In some embodiments, the target gene includes the herpes simplex virus thymidine kinase (HSV-TK) gene or the BAX gene.
[0026] In some embodiments, the target gene comprises the nucleotide sequence shown in SEQ ID NO: 15 or 17 or the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 16 or 18.
[0027] In some embodiments, the modified virus further includes a gene encoding a transcription activator that can enhance the function of the cis-acting element.
[0028] In some embodiments, the transcription activator includes a transcription activation domain.
[0029] In some embodiments, the transcriptional activation domain includes VPR (VP64-p65-Rta), HEB transcriptional activation domain, VP16 transcriptional activation domain, and / or P300 transcriptional activation domain.
[0030] In some embodiments, the VPR comprises the amino acid sequence shown in SEQ ID NO: 29.
[0031] In some embodiments, the HEB transcription activation domain comprises the amino acid sequence shown in SEQ ID NO: 30.
[0032] In some embodiments, the VP16 transcriptional activation domain comprises the amino acid sequence shown in SEQ ID NO: 31.
[0033] In some embodiments, the P300 transcription activation domain comprises the amino acid sequence shown in SEQ ID NO: 32.
[0034] In some embodiments, the transcription activator is capable of binding to the same PAX family transcription factors that bind to the cis-acting element.
[0035] In some embodiments, the transcription activator includes a first domain and a second domain, wherein the first domain is capable of binding to the same PAX family transcription factors that bind to the cis-acting element, and the second domain includes a transcription activation domain.
[0036] In some embodiments, the first structural domain and the cis-acting element can be combined with PAX3-FOXO1.
[0037] In some embodiments, the first domain comprises a lysine-specific demethylase 4B (KDM4B) truncated form.
[0038] In some embodiments, the lysine-specific demethylase 4B (KDM4B) truncated variant comprises the amino acid sequence shown in SEQ ID NO: 28.
[0039] In some embodiments, the transcription activator comprises the amino acid sequence shown in SEQ ID NO: 33, 35, 37 or 39.
[0040] In some embodiments, the gene encoding the transcription activator comprises the nucleotide sequence shown in SEQ ID NO: 34, 36, 38 or 40.
[0041] In some embodiments, the gene encoding the transcription activator is located at the 5' or 3' end of the target gene.
[0042] In some embodiments, it further includes a polyadenylated nucleotide signal sequence located at the 3' end of the target gene.
[0043] In some embodiments, the number of copies of the cis-acting element, which is oriented in the 5' to 3' direction and capable of binding to a fusion protein containing a PAX family transcription factor, and the target gene operatively linked to the cis-acting element, may be one or more.
[0044] In some embodiments, the cis-acting element, which is oriented in the 5' to 3' direction and capable of binding to a fusion protein containing a PAX family transcription factor, and a target gene operatively linked to the cis-acting element, are integrated into the genome of the modified virus.
[0045] In some embodiments, the integration includes the use of gene editing and / or gene recombination.
[0046] In some embodiments, the virus is selected from the group consisting of: adenovirus, vaccinia virus, herpes simplex virus, parvovirus, reovirus, Coxsackie virus, Seneca Valley virus, Semliki Forest virus, poliovirus, measles virus, Newcastle disease virus, vesicular stomatitis virus, Venezuelan equine encephalitis virus, chicken anemia virus, Malaba virus, and echovirus.
[0047] In some embodiments, the modified virus comprises the nucleotide sequences shown in any one of SEQ ID NO: 25-27 and SEQ ID NO: 46-48.
[0048] On the other hand, this application provides an expression cassette comprising, in the 5' to 3' direction, a cis-acting element capable of binding to a fusion protein containing a PAX family transcription factor and a target gene operatively linked to the cis-acting element, wherein the cis-acting element comprises a domain that binds to a PAX family transcription factor, and the domain that binds to a PAX family transcription factor comprises the nucleotide sequence shown in SEQ ID NO: 1.
[0049] In some embodiments, the cis-acting element comprises a nucleotide sequence shown in any one of SEQ ID NO: 7-10.
[0050] In some embodiments, the target gene includes genes essential for viral replication.
[0051] In some embodiments, the target gene includes a suicide gene.
[0052] In some embodiments, the expression cassette further includes a gene encoding a transcription activator that enhances the function of the cis-acting element.
[0053] In some embodiments, the expression cassette comprises the nucleotide sequences shown in any one of SEQ ID NO: 25-27 and SEQ ID NO: 46-48.
[0054] On the other hand, this application provides an isolated nucleic acid molecule comprising, in the 5' to 3' direction, a nucleotide sequence encoding a cis-acting element capable of binding to a fusion protein containing a PAX family transcription factor and a target gene nucleotide sequence operatively linked to said cis-acting element, wherein the cis-acting element includes a PAX family transcription factor-binding domain, and said PAX family transcription factor-binding domain includes the nucleotide sequence shown in SEQ ID NO: 1. On the other hand, this application provides an isolated nucleic acid molecule encoding the expression cassette described in this application. On the other hand, this application provides an isolated nucleic acid molecule encoding the modified virus described in this application.
[0055] On the other hand, this application provides a vector containing the isolated nucleic acid molecules described in this application. In some embodiments, the vector includes a viral vector.
[0056] On the other hand, this application provides a cell comprising the modified virus described in this application, the isolated nucleic acid molecule described in this application, and / or the vector described in this application.
[0057] On the other hand, this application provides a pharmaceutical composition comprising the modified virus described in this application, the isolated nucleic acid molecule described in this application, the vector described in this application, and / or the cell described in this application, and optionally a pharmaceutically acceptable carrier.
[0058] On the other hand, this application provides the use of the modified virus described in this application, the isolated nucleic acid molecule described in this application, the vector described in this application, and / or the cell described in this application in the preparation of a drug, wherein the drug is used to treat tumors.
[0059] On the other hand, this application provides the use of the modified virus described in this application, the isolated nucleic acid molecule described in this application, the vector described in this application, the cell described in this application, and / or the pharmaceutical composition described in this application in the treatment of tumors.
[0060] On the other hand, this application provides a method for treating tumors, comprising administering to a subject in need an effective amount of the modified virus described in this application, the isolated nucleic acid molecule described in this application, the vector described in this application, the cell described in this application, and / or the pharmaceutical composition described in this application.
[0061] In some embodiments, the tumor includes a tumor associated with a fusion protein containing PAX family transcription factors.
[0062] In some embodiments, the tumor includes tumors associated with PAX3-FOXO1, PAX7-FOXO1, PAX3-MAML3, PAX3-NOCA1, PAX3-NOCA2, PAX5-ETV6, PAX5-ELN, PAX7-PPARGC1A, PAX8-GLIS3 and / or PAX8-PPARG.
[0063] In some embodiments, the tumor is selected from one or more of the following groups: rhabdomyosarcoma, biphenotypic sinus sarcoma, B-cell lymphoma, and thyroid tumor.
[0064] Other aspects and advantages of this application will readily be apparent to those skilled in the art from the detailed description below. Only exemplary embodiments of this application are shown and described in the following detailed description. As will be appreciated by those skilled in the art, the content of this application enables them to make modifications to the disclosed specific embodiments without departing from the spirit and scope of the invention to which this application pertains. Accordingly, the descriptions in the accompanying drawings and specification of this application are merely exemplary and not restrictive. Attached Figure Description
[0065] The specific features of the invention involved in this application are shown in the appended claims. The features and advantages of the invention can be better understood by referring to the exemplary embodiments and drawings described in detail below. A brief description of the drawings is as follows:
[0066] Figures 1A-1G show the cis-acting elements described in this application that can bind to and respond to fusion proteins containing PAX family transcription factors. Figure 1A shows a schematic diagram of detecting the function of the cis-acting elements described in this application using SEAP as a reporter gene. Figure 1B shows the function of cis-acting elements containing PAX family transcription factor-binding domains of different copy numbers (each group from left to right: PcDNA3.1, PAX3, FOXO1, PAX-FOXO1). Figure 1C shows the response of the cis-acting elements described in this application to different concentrations of PAX3-FOXO1 fusion protein. Figures 1D-1G show the response of the cis-acting elements described in this application to different fusion proteins and their corresponding wild-type transcription factors.
[0067] Figures 2A-2C illustrate the specific response of the cis-acting element described in this application to fusion proteins within tumor cells. Figure 2A shows a schematic diagram of detecting the function of the cis-acting element described in this application using EGFP as a reporter gene. Figures 2B-2C show the function of the cis-acting element described in this application in different cell lines.
[0068] Figures 3A-3E illustrate the operative linking of the cis-acting element described in this application to various therapeutic genes. Figure 3A shows a schematic diagram illustrating the operative linking of the cis-acting element described in this application to the suicide gene HSV-TK to exert a therapeutic effect. Figures 3B-3C show the operative linking of the cis-acting element described in this application to the suicide gene HSV-TK to achieve a killing effect on tumor cells. Figure 3D shows a schematic diagram illustrating the use of the cis-acting element described in this application in oncolytic viruses to exert a therapeutic effect. Figure 3E shows that an oncolytic adenovirus containing the cis-acting element described in this application and its operatively linked E1A can achieve a killing effect on fusion gene-positive tumor cells.
[0069] Figures 4A-4F show the distribution of signals in different organs and tissues after the cis-acting element described in this application is operably linked to luciferase and packaged into an adeno-associated virus vector.
[0070] Figure 5 shows a schematic diagram of the process for preparing the modified oncolytic virus described in this application.
[0071] Figures 6A-6D show the in vitro killing effect of the modified oncolytic virus described in this application. Figure 6A shows a schematic diagram of the principle of the modified oncolytic adenovirus described in this application. Figures 6B-6D show the in vitro killing effect of the modified oncolytic adenovirus described in this application on different cell lines, verified by CCK8 apoptosis rate detection technology and crystal violet staining technology, respectively.
[0072] Figures 7A-7D show the in vivo oncolytic effect of the modified oncolytic virus described in this application. Figure 7A shows a schematic flowchart of the oncolytic virus function verification in mice. Figure 7B shows the tumor size of RH30 tumor-bearing mice after oncolytic virus treatment. Figure 7C shows the change in tumor volume of RH30 tumor-bearing mice after oncolytic virus treatment. Figure 7D shows the tumor mass of RH30 tumor-bearing mice after oncolytic virus treatment.
[0073] Figures 8A and 8B show the cis-acting element signal amplification system described in this application. Figure 8A shows the construction principle of the cis-acting element signal amplification system described in this application. Figure 8B shows the response of the cis-acting element signal amplification system described in this application to fusion proteins containing PAX family transcription factors (each group from left to right: PcDNA3.1, PAX3, PAX-FOXO1).
[0074] Figures 9A-9H show the in vivo oncolytic effect of the modified oncolytic virus described in this application. Figure 9A shows the experimental procedure. Figures 9B-9D show the tumor-killing effect of the oncolytic virus containing the cis-acting element signal amplification system on RH30 tumor-bearing mice. Figures 9E-9G show the tumor-killing effect of the oncolytic virus containing the cis-acting element signal amplification system on RD tumor-bearing mice. Figure 9H shows the tumor specificity of the oncolytic virus described in this application.
[0075] Figures 10A-10B show a comparison of different cis-acting elements.
[0076] Figures 11A-11G show the in vitro and in vivo killing function of the modified virus against patient-derived tumor cells. Figure 11A shows the detection results of the PAX3-FOXO1 fusion gene expression level in patient-derived rhabdomyosarcoma samples. Figure 11B shows the expression level of the fusion gene in ARMS-1. Figures 11C and 11D show the in vitro killing effect of the modified oncolytic adenovirus described in this application against ARMS-1, verified by CCK8 apoptosis rate detection technology and crystal violet staining technology, respectively. Figure 11E shows a schematic diagram of the experimental procedure for the oncolytic effect of the modified oncolytic virus described in this application on patient-derived tumor cells (ARMS-1, ARMS-2) in vivo. Figure 11F shows the oncolytic effect of the modified oncolytic virus described in this application on patient-derived tumor cells in vivo. Figure 11G shows the survival curve of tumor mice after intratumoral injection of the oncolytic virus described in this application. Detailed Implementation
[0077] The following specific embodiments illustrate the implementation of the invention. Those skilled in the art can easily understand other advantages and effects of the invention from the content disclosed in this specification.
[0078] Terminology Definition
[0079] In this application, the term "virus" can include live viruses, inactivated viruses, virus particles, viral inclusion bodies, virions, virus-like particles, viral components, and mixtures thereof, and may also include viral genomes. In this application, the term "modified virus" generally refers to a virus that has been altered compared to its parent strain. Typical modified viruses have one or more truncations, mutations, insertions, or deletions in their viral genome. Modified viruses may have one or more modified endogenous viral genes and / or one or more modified intergenic regions. Modified viruses may have one or more heterologous nucleotide sequences inserted into the viral genome. For example, modified viruses may have one or more heterologous nucleotide sequences in the form of gene expression cassettes to express heterologous genes. For example, modified viruses may have heterologous cis-acting elements. For example, in modified viruses, said cis-acting elements can regulate endogenous viral genes and / or heterologous nucleic acid sequences. In this application, the term "oncolytic virus" generally refers to a virus that can selectively replicate in tumor cells in vitro or in vivo and slow the growth of tumor cells or induce or overproliferate cell death, while having no effect or minimal effect on normal cells.
[0080] In this application, the term "PAX family transcription factor" is used interchangeably with "PAX transcription factor family" or "PAX transcription factor." In this application, the PAX family transcription factor can include any naturally occurring PAX family transcription factor from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats), unless otherwise specified. The PAX family transcription factor can include "full-length," unprocessed PAX family transcription factors, and any form of PAX family transcription factor derived from cell processing; it can also include naturally occurring variants of PAX family transcription factors, such as splice variants or allelic variants. In this application, PAX family transcription factors generally belong to the category of transcription activators.
[0081] In this application, each of the terms "chimeric protein," "fusion protein," or "fusion polypeptide" refers to a protein whose amino acid sequence represents a fusion product of subsequences derived from amino acid sequences of at least two different proteins. Fusion proteins are typically not produced by direct manipulation of the amino acid sequence, but rather, rather, from the expression of a "chimeric" gene encoding the chimeric amino acid sequence. In this application, fusion proteins containing PAX family transcription factors can be derived from gene expression following gene rearrangement or gene fusion. Fusion proteins containing PAX family transcription factors can retain the DNA-binding domains (such as paired-box domains) of PAX proteins and fuse with functional domains of partner proteins (such as transcription activation domains or phase-separation tendency domains) to form chimeras with anomalous transcriptional regulatory capabilities. Chimeric proteins containing PAX family transcription factors may include, but are not limited to: PAX3-FOXO1, PAX7-FOXO1, PAX3-MAML3, PAX3-NOCA1, PAX3-NOCA2, PAX5-ETV6, PAX5-ELN, PAX7-PPARGC1A, PAX8-GLIS3, and / or PAX8-PPARG. Fusion proteins containing PAX family transcription factors typically retain the DNA recognition capabilities of PAX proteins; for example, fusion proteins containing PAX family transcription factors often include full-length or partially derived DNA-binding domains from one or more PAX family transcription factors.
[0082] In this application, the term "target gene" generally refers to exogenous DNA or cDNA that encodes a gene product contained in a nucleic acid molecule, vector, host cell, or kit, said gene product may be a polypeptide, protein, or a polynucleotide that is functional or active (e.g., antisense DNA, miRNA, siRNA, and shRNA).
[0083] In this application, the term "cis-acting element" generally refers to a regulatory element of gene expression that can affect gene expression. Typically, a cis-acting element is a nucleotide sequence located at or near the 5' end, 3' end, both ends, and / or inside the gene sequence it regulates. Cis-acting elements generally do not encode any protein; they merely provide a site of action to influence gene expression through interaction with trans-acting factors. "Trans-acting factors" generally refer to various molecules that exert different regulatory effects (activation or inhibition) on gene expression by directly binding to or indirectly acting on nucleic acid molecules such as DNA and RNA. Generally, trans-acting factors refer to specific proteins that can bind to gene sequences, i.e., transcription factors. Cis-acting elements can regulate gene expression by binding to transcription factors; in this application, this process can also be referred to as the "response" of a cis-acting element to a transcription factor. Cis-acting elements contain a binding site for transcription factors. The regulation of genes by cis-acting elements can include positive or negative regulation. For example, when a cis-acting element positively regulates a gene, the activity and / or expression of the regulated gene is activated and / or upregulated after the cis-acting element binds to its corresponding transcription factor. Conversely, when a cis-acting element negatively regulates a gene, the activity and / or expression of the regulated gene is silenced and / or downregulated after the cis-acting element binds to its corresponding transcription factor. The types of cis-acting elements may include, but are not limited to, promoters and enhancers.
[0084] In this application, the term "transcription factor" generally refers to a class of protein or polypeptide molecules that can bind to specific sequences on DNA and regulate gene transcription. Transcription factors regulate gene transcriptional activity by binding to specific sequences on DNA, affecting the binding of RNA polymerase to gene promoter regions. In this application, the term "DNA-binding domain" generally refers to a portion of a molecular structure designed to bind to specific sequences on DNA. These domains typically include specific amino acid sequences or structural motifs capable of forming stable interactions with specific sequences in DNA. DNA-binding domains can include the DNA-binding domains of transcription factors; this binding typically occurs in gene promoter regions and can promote or inhibit gene transcription. In this application, the term "transcription activator" generally refers to a protein or polypeptide molecule capable of enhancing gene transcription. The term "transcription activation domain" generally refers to a regulatory element or functional region for enhancing or activating the transcription of a target gene.
[0085] In this application, the term "operable link" generally refers to the arrangement of two or more nucleic acid sequence elements that are physically linked and have a functional relationship with each other. For example, an operable link may include placing a regulatory sequence necessary for the expression of a coding sequence in an appropriate position relative to the coding sequence to achieve the expression of the coding sequence. For example, an operable link may represent the arrangement of a target gene sequence and a cis-acting element sequence. For example, if the cis-acting element sequence can affect the transcription or expression of the target gene sequence, then the target gene and the cis-acting element are operably linked. In some embodiments, "operable link" may also refer to the linking of a target gene to a vector such that the gene regulatory sequence within the vector performs its intended function of regulating the transcription and translation of the target gene.
[0086] In this application, the term "binding" generally refers to a physical or chemical interaction between two or more biomolecules or compounds. Binding includes ionic, nonionic, hydrogen bonding, van der Waals, hydrophobic interactions, etc. Binding can be direct or indirect; indirect binding is due to or through the influence of another biomolecule or compound. Direct binding refers to an interaction that occurs not due to or through the influence of another biomolecule or compound, but without any other substantial chemical intermediate. Binding can include specific binding.
[0087] In this application, the term "promoter" generally refers to the essential nucleotide sequence used to drive transcription of downstream (3' end) or upstream (5' end) nucleotide sequences. Promoters are typically located near the gene they transcribe. In this application, a promoter may include a functional segment of the promoter. For example, the functional segment of the promoter may consist of fewer polynucleotides than the promoter itself, but still retain the ability to drive transcription. In this application, the term "inducible promoter" generally refers to promoters that can be activated or induced under specific conditions, regulating the expression of the gene associated with them in a specific environmental or physiological state. These promoters are typically influenced by external signals or regulatory elements, which, when present, drive the transcriptional activity of the gene.
[0088] In this application, the term "minimal promoter" generally refers to the smallest functional segment capable of initiating transcription. For example, a promoter can refer to a nucleotide sequence containing a minimal promoter plus regulatory elements capable of controlling the expression of a coding sequence or functional RNA. A minimal promoter may contain the promoter's basic TATA box element, where RNA polymerase II (polII), TATA-binding protein (TBP), and / or TBP-associated factor (TAF) can bind to initiate transcription. A minimal promoter may contain at least one TATA box element. In this application, the term "TATA box" generally refers to a segment in the promoter resembling a 5'-TATAAA-3' nucleotide sequence. The TATA box is typically located 25-35 nucleotides upstream of the transcription start site of the target gene.
[0089] Minimal promoters can be derived from viruses, such as the SV40 early or late promoter, the cytomegalovirus (CMV) immediate early promoter, or the Raúl's sarcoma virus (RSV) early promoter; or from eukaryotic promoters, such as the β-actin promoter, GADPH promoter, TK-1 (thymidine kinase) promoter, HSP (heat shock protein) promoter, UbB or UbC promoter, PGK, Ef1-α promoter, or any eukaryotic promoter containing a TATA box element. In this application, the term "minimal CMV promoter" generally refers to the shortest sequence derived from the cytomegalovirus immediate early promoter that has transcriptional-driving functionality. For example, a minimal CMV promoter may contain the nucleotide sequence shown in SEQ ID NO: 6.
[0090] In this application, the term "enhancer" generally refers to a regulatory DNA sequence that can be bound by a protein (activator protein) to stimulate or enhance the transcription of one or more genes. Enhancers are typically cis-acting but can be located upstream or downstream of the transcription start site of a gene or the genes they regulate. Furthermore, enhancers can be forward or backward and do not need to be located near the transcription start site to influence transcription. Enhancers can also be located within introns.
[0091] In this application, the term "replication" generally refers to an increase in quantity. For example, viral replication can include viral duplication. Viral duplication can include any virus-mediated biological pathway required to complete the transcription and / or translation of the viral genome and / or the formation of viral packaging and / or functional virions and / or the budding of neovirions from the target host cell membrane. "Viral replication-essential genes" generally refers to viral genes that are essential for viral replication in vivo or in tissue cultures. For example, if viral replication-essential genes are missing or their function is impaired, the virus will be unable to complete the replication process.
[0092] In this application, the terms "5'" and "3'" are conventional expressions used to describe the characteristics of nucleotide sequences, relating to the location of genetic elements and / or the direction (5' to 3') of events such as RNA polymerase transcription or ribosomal translation that occur in a 5' to 3' direction. Synonyms are upstream (5') and downstream (3'). Typically, DNA sequences, gene maps, vector maps, and RNA sequences are drawn from left to right in a 5' to 3' direction, or the 5' to 3' direction is indicated by an arrow symbol where the arrow points in the 3' direction. Therefore, when following this conventional usage, 5' (upstream) refers to the genetic element being placed to the left, while 3' (downstream) refers to the genetic element being placed to the right.
[0093] In this application, the term "gene editing" generally refers to genetic engineering that modifies nucleotide sequences, including the insertion, deletion, modification, or substitution of DNA in the genome of an organism. In this application, gene editing can be performed using enzymes, such as nucleases engineered to target specific DNA sequences, which can introduce cleavage into the DNA strand, thereby enabling the removal of existing DNA and the insertion of substituted DNA. Gene editing can be performed using a CRISPR / Cas system.
[0094] In this application, the term "genetic recombination" generally refers to the exchange of genetic material between multiple chromosomes and / or between different regions of the same chromosome. Genetic recombination can be mediated by homology; that is, homologous regions of chromosomes align themselves in preparation for exchange and may require some degree of sequence identity.
[0095] In this application, the term "suicide gene" generally refers to a gene that encodes a protein possessing an inducible ability to cause cell death. For example, a suicide gene may include a gene encoding a protein that induces apoptosis. For example, a suicide gene may include a gene encoding an enzyme that converts a prodrug into a cellularly toxic compound. A suicide gene may include a gene encoding a protein having cytosine deaminase (CDase) activity, thymidine kinase activity, uracil phosphoribosyltransferase (UPRTase) activity, purine nucleoside phosphorylase activity, and thymidine kinase activity. Examples of suicide genes include, but are not limited to, genes encoding herpes simplex virus thymidine kinase (HSV-TK), which can convert the prodrug ganciclovir (GCV) into a cellularly toxic metabolite; and genes encoding cytosine deaminase, which can convert 5-fluorocytosine (5-FC) into 5-fluorouracil, which has antitumor activity.
[0096] In this application, the term "immune response" or "immunological response" generally includes T cell-mediated and / or B cell-mediated immune responses. Exemplary immune responses include T cell responses, such as cytokine production and cytotoxicity. Furthermore, the term immune response includes immune responses indirectly influenced by T cell activation, such as antibody production (humoral response) and activation of cytokine-responsive cells such as macrophages. Immune cells involved in the immune response include lymphocytes such as B cells and T cells (e.g., CD4+). + CD8 + Th1 and Th2 cells); antigen-presenting cells (e.g., professional antigen-presenting cells such as dendritic cells, macrophages, B lymphocytes, Langerhans cells, etc., and non-professional antigen-presenting cells such as endothelial cells, fibroblasts and epithelial cells); bone marrow cells such as macrophages, eosinophils, mast cells, basophils and neutrophils.
[0097] In this application, the term "cytokine" generally refers to a protein released by a population of cells that acts as an intercellular regulator in another cell. For example, the cytokine may include cytokines that can be used for tumor therapy. Examples of "cytokines" include, but are not limited to, interleukins, tumor necrosis factor, interferons, chemokines, lymphokines, and / or growth factors.
[0098] In this application, the terms "polyadenylation signal sequence" or "polyA signal sequence" generally refer to nucleotide sequences used to induce the cleavage and polyadenylation of primary transcripts in specific nucleotide sequence segments.
[0099] In this application, the term "vector" generally refers to a nucleic acid molecule capable of transporting another nucleic acid linked to it. One type of vector is the "plasmid," which refers to a circular double-stranded DNA loop into which other DNA segments can be linked. Another type of vector is the viral vector. In this application, the term "viral vector" generally refers to a nucleic acid delivery vehicle constructed based on a viral genome, capable of carrying exogenous nucleotide sequences. Typically, a viral vector can self-replicate and / or express its contained genes (endogenous and exogenous) in a suitable host cell. A viral vector may contain the complete genome of a wild-type virus, or a mutated or modified viral genome.
[0100] In this application, the term "treatment" generally refers to slowing or improving the progression, severity, and / or duration of a proliferative condition, or improving one or more symptoms of a proliferative condition (e.g., one or more identifiable symptoms), due to the application of one or more therapies (e.g., one or more therapeutic agents such as the modified virus of this application). In this application, the term "treatment" may also refer to improving at least one measurable physical parameter of a proliferative condition, such as tumor growth, which need not be identifiable to the patient. The term "treatment" in this application may also refer to inhibiting the progression of a proliferative condition physically, for example, by stabilizing identifiable symptoms, physiologically, for example, by stabilizing physical parameters, or both. In some cases, the term "treatment" may refer to reducing or stabilizing tumor size or cancer cell count.
[0101] In this application, the term "pharmaceutical composition" generally refers to a formulation in a form that allows for the effective biological activity of the active ingredient and does not contain any additional ingredients that would have unacceptable toxicity to the subject to whom the formulation is to be administered. The pharmaceutical composition may also contain one or more pharmaceutically acceptable carriers. The acceptable components of the pharmaceutical composition are preferably non-toxic to the recipient at the dosage and concentration used. The pharmaceutical compositions of the present invention include, but are not limited to, liquid, freeze-dried, and lyophilized compositions.
[0102] In this application, the term "pharmaceutically acceptable carrier" generally refers to any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and absorption delay agents that are compatible with drug administration. The use of such media and reagents for pharmaceutically active substances is well known in the art. Unless incompatible with the active compound, any conventional media or reagent may be considered for use in the pharmaceutical compositions of this application.
[0103] In this application, the terms "tumor" or "tumor cell" generally refer to or describe a physiological condition characterized by unregulated cell growth. For example, a tumor can refer to the proliferation and growth of neoplastic cells. For example, a tumor described in this application can include cancer. For example, tumor cells described in this application can include cancer cells.
[0104] In this application, the term "cancer" generally refers to a new growth formed when a cell in a local tissue loses normal regulation of its growth at the gene level under the influence of various carcinogenic factors, resulting in its clonal abnormal proliferation. Because such new growths often present as space-occupying, mass-like protrusions, they are also called neoplasms. The term "cancer" includes primary malignant tumors (e.g., malignant tumors whose cells do not migrate to sites other than the original tumor site in the individual's body) and secondary malignant tumors (e.g., those malignant tumors caused by metastasis, where tumor cells migrate to a second site different from the original tumor site).
[0105] In this application, the term "tumor associated with a fusion protein containing PAX family transcription factors" generally refers to a tumor associated with cells expressing or containing a fusion protein containing PAX family transcription factors. For example, said tumor associated with PAX family transcription factors may include tumors induced or promoted by gene rearrangements leading to the formation of fusion proteins between PAX family transcription factors and other protein domains, and through abnormal regulation of cell proliferation, differentiation, or apoptosis pathways. In tumors or tumor cells abnormally associated with fusion proteins containing PAX family transcription factors, fusion proteins containing PAX family transcription factors or nucleic acids encoding them can be detected. Methods for detecting fusion proteins containing PAX family transcription factors or their expression in tumors are known in the art and include Western blot and immunohistochemical assays.
[0106] In this application, the term "expression level" generally refers to the protein, RNA, or mRNA level of a specific related gene. Any method known in the art can be used to determine the expression level of a specific related gene (e.g., human PAX family transcription factors). In this application, "expression" generally refers to the process of transforming gene-encoded information into structures present in and operating within cells. This can include, for example, reverse transcription and amplification analysis (e.g., PCR, reverse transcription RT-PCR, or quantitative qPCR), hybridization analysis, Northern blotting, dot blot blotting, in situ hybridization, gel electrophoresis, capillary electrophoresis, column chromatography, Western blotting, immunohistochemistry, immunostaining, or mass spectrometry. Analysis can be performed directly on biological samples or on proteins / nucleic acids isolated from samples.
[0107] In this application, the term "activity" generally refers to the functional property or property of a substance. For transcription factors, the term "activity" relates to their ability to regulate gene transcription. The transcriptional activity of a gene can be determined using conventionally used analyses such as reporter gene analysis.
[0108] In this application, the term "expression cassette" generally refers to a recombinantly or synthetically produced polynucleotide having a series of designated nucleic acid elements that allow specific nucleic acids to be transcribed in target cells. Generally, an expression cassette may include the nucleotide sequence to be transcribed and a promoter, along with other sequences.
[0109] In this application, the terms "nucleic acid," "polynucleotide," and "oligonucleotide" generally refer to polymers of nucleotides (e.g., ribonucleotides or deoxyribonucleotides) and include naturally occurring (adenine, guanine, cytosine, uracil, and thymine), non-natural, and modified nucleic acids. The term is not limited by the length of the polymer (e.g., the number of monomers). Nucleic acids can be single-stranded or double-stranded and generally contain 5'-3' phosphodiester bonds, although in some cases, nucleotide analogs may have other linkages. Monomers are generally referred to as nucleotides. The term "nucleotide sequence" used in this application generally refers to a specific arrangement of nucleotides in a nucleic acid molecule.
[0110] In this application, the term "isolated" generally refers to biological components (such as nucleic acid molecules, proteins, viruses, or cells) that have been purified to be substantially free of other cellular components (such as other chromosomes and extrachromosomal DNA and RNA, proteins, and cells) associated with them in their natural state. Isolated nucleic acid molecules and proteins include those purified by standard purification methods. The term also includes nucleic acid molecules and proteins obtained through recombinant expression in host cells, as well as chemically synthesized nucleic acid molecules and proteins.
[0111] In this application, the terms "subject," "individual," "animal," or "patient" are used interchangeably to refer to a subject for whom administration of the pharmaceutical composition of this application is necessary, such as a mammalian subject. Animal subjects include humans, non-human primates, dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, dairy cows, etc., such as humans.
[0112] In this application, the terms “identity,” “homology,” and their grammatical variations generally refer to the fact that two or more entities are “aligned” sequences, meaning they are identical. Thus, for example, when two polypeptide sequences are identical, they have the same amino acid sequence at least within a referenced region or portion. If two polynucleotide sequences are identical, they have the same polynucleotide sequence at least within a referenced region or portion. Identity can be a defined region (region or domain) of a sequence. A “region” or “domain” of identity refers to the same portion of two or more referenced entities. Thus, if two protein or nucleic acid sequences are identical in one or more sequence regions or domains, they are identical within that region. An “aligned” sequence refers to multiple polynucleotide or protein (amino acid) sequences that, compared to a reference sequence, often contain corrected deletions or additional bases or amino acids (gap). The degree of identity (homology) between two sequences can be determined using computer programs and mathematical algorithms. Such algorithms for calculating percentage sequence identity (homology) generally calculate sequence gaps and mismatches within the compared regions or domains. For example, the BLAST (e.g., BLAST 2.0) search algorithm (see, e.g., Altschul et al., J.Mol.Biol.215:403(1990), publicly available through NCBI) has exemplary search parameters as follows: mismatch -2, gap open 5, gap extend 2.
[0113] In this application, the term "comprising" generally means including the explicitly specified features, but does not exclude other elements.
[0114] In this application, the term "about" generally refers to a variation within a range of 0.5% to 10% above or below a specified value, such as a variation within a range of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below a specified value.
[0115] Invention Details
[0116] Cis-acting element
[0117] On the one hand, this application provides a cis-acting element capable of binding to a fusion protein containing PAX family transcription factors. The cis-acting element provided in this application can regulate the expression of a target gene operatively linked to it.
[0118] Current research indicates that PAX family transcription factors are closely related to the occurrence, development, and metastasis of cancer. Therefore, this application proposes to construct cis-acting elements that respond to fusion proteins (e.g., PAX3-FOXO1).
[0119] In some embodiments, the cis-acting element is capable of binding to a fusion protein containing PAX family transcription factors, and upon binding to the fusion protein containing PAX family transcription factors, the gene activity and / or expression regulated by the cis-acting element can be activated and / or upregulated. For example, the cis-acting element is capable of binding to one or more fusion proteins containing PAX family transcription factors. In some embodiments, the cis-acting element is capable of specifically binding to one or more fusion proteins containing PAX family transcription factors, such that the gene activity and / or expression it regulates can be specifically activated and / or upregulated in cells containing fusion proteins containing PAX family transcription factors. For example, the activation and / or upregulation of gene activity and / or expression regulated by the cis-acting element may be relative to the gene activity and / or expression regulated by the cis-acting element in cells where fusion proteins containing PAX family transcription factors are absent, relative to the gene activity and / or expression regulated by the cis-acting element in normal cells of a subject, cells of a normal healthy subject, and / or normal healthy cells, or relative to gene activity and / or expression not regulated by the cis-acting element.
[0120] In some embodiments, the gene regulated by the cis-acting element is inactive and / or not expressed in the normal cells of the subject, the cells of a normal healthy subject, and / or normal healthy cells. In some embodiments, the gene regulated by the cis-acting element has low activity and / or low expression levels in the normal cells of the subject, the cells of a normal healthy subject, and / or normal healthy cells. For example, low gene activity and / or low expression levels may be relative to gene activity and / or expression regulated by the cis-acting element in cells containing fusion proteins comprising PAX family transcription factors, relative to gene activity and / or expression regulated by the cis-acting element in tumor cells, or relative to gene activity and / or expression not regulated by the cis-acting element.
[0121] In some embodiments, the activity of the gene may include the functional properties or properties of the gene and / or the polynucleotides corresponding to the functional segments of the gene (e.g., polynucleotides encoding the gene, messenger RNA (mRNA) produced by gene transcription, etc.), amino acid products, proteins and / or post-translational modified proteins.
[0122] In some embodiments, the expression level of the gene may include the amount of the gene and / or the polynucleotide corresponding to the functional segment of the gene (e.g., the polynucleotide encoding the gene, the messenger RNA (mRNA) generated by gene transcription, etc.), amino acid products, proteins and / or post-translational modified proteins.
[0123] In some embodiments, the cis-acting element includes a domain that binds to PAX family transcription factors. For example, the PAX family transcription factor-binding domain can bind to the DNA-binding domain of the PAX family transcription factor. The fusion protein containing PAX family transcription factors described in this application may contain the DNA-binding domain of the PAX family transcription factor. For example, the fusion protein containing PAX family transcription factors can bind to the PAX family transcription factor-binding domain in the cis-acting element described in this application via the DNA-binding domain of the PAX family transcription factor.
[0124] In this application, the domain binding to the PAX family transcription factor comprises the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the domain binding to the PAX family transcription factor is the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the domain binding to the PAX family transcription factor comprises the amino acid sequence shown in any one of SEQ ID NO: 2-5. In some embodiments, the domain binding to the PAX family transcription factor is the amino acid sequence shown in any one of SEQ ID NO: 2-5.
[0125] In some embodiments, the PAX family transcription factor binding domain may comprise n PAX family transcription factor binding domains, where n is an integer greater than or equal to 1. In some embodiments, n may be an integer between 1 and 15. In some embodiments, n may be 15. In some embodiments, the PAX family transcription factor binding domain may comprise n CGTGACTAAT, where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, spacer sequences may be included between the DNA-binding domains of the repeating PAX family transcription factors. For example, one or more nucleotides may be included as spacer sequences between the DNA-binding domains of the repeating PAX family transcription factors. For example, one or two G (guanine), A (adenine), C (cytosine), and / or T (thymine) spacer sequences may be included between the DNA-binding domains of two consecutive PAX family transcription factors. In some embodiments, the DNA-binding domains of the repeated PAX family transcription factors may not contain spacer sequences.
[0126] In some embodiments, the cis-acting element may be a polynucleotide sequence. In some embodiments, the cis-acting element may comprise the nucleotide sequence shown in any one of SEQ ID NO: 7-10.
[0127] In some embodiments, the cis-acting element may also include components other than the domain that binds to PAX family transcription factors.
[0128] In some embodiments, the cis-acting element can drive the transcription of the gene it regulates. In some embodiments, the cis-acting element can be a promoter, comprising a domain that binds to PAX family transcription factors and a component that drives transcription. For example, the component that drives transcription is a minimal promoter.
[0129] In some embodiments, the cis-acting element comprises a PAX family transcription factor-binding domain and a minimal promoter. In some embodiments, the PAX family transcription factor-binding domain may be directly adjacent to the minimal promoter or separated by an inserted nucleotide. In some embodiments, the minimal promoter may be located at the 3' end of the PAX family transcription factor-binding domain.
[0130] In some implementations, the minimum promoter may contain at least one TATA box. For example, the minimum promoter may be a nucleotide sequence of at least one TATA box.
[0131] In some embodiments, the minimal promoter may be derived from a viral promoter, such as the SV40 early or late promoter or the Raúl's sarcoma virus (RSV) early promoter; or it may be derived from a eukaryotic promoter, such as the β-actin promoter, GADPH promoter, TK-1 (thymidine kinase) promoter, HSP (heat shock protein) promoter, UbB or UbC promoter, PGK, EF1-α promoter, or any eukaryotic promoter containing a TATA box. In some embodiments, the minimal promoter may be tissue-specific, such as one of the muscle cell-specific promoters: the minimal TnISlow promoter, the minimal TnIFast promoter, or the muscle creatine kinase promoter.
[0132] In some embodiments, the minimal promoter may be a minimal CMV (cytomegalovirus) promoter. In some embodiments, the minimal promoter may be a minimal human CMV promoter (P... hCMVmini In some embodiments, the minimal promoter may comprise the nucleotide sequence described in SEQ ID NO: 6.
[0133] In some embodiments, the cis-acting element may comprise a nucleotide sequence shown in any one of SEQ ID NO: 7-10. In some embodiments, the cis-acting element may comprise a nucleotide sequence having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identity with a nucleotide sequence shown in any one of SEQ ID NO: 7-10.
[0134] In some embodiments, the cis-acting element described in this application can be a tumor-specific promoter. For example, the tumor-specific promoter can have high tumor specificity and high promoter activity, and can be effectively used for gene therapy.
[0135] In some embodiments, the cis-acting element can enhance the transcriptional level of the gene it regulates. In some embodiments, the cis-acting element can be an enhancer. In some embodiments, the cis-acting element can be a tumor-specific enhancer.
[0136] Expression Box
[0137] On the other hand, this application also provides an expression cassette comprising the cis-acting element described in this application and a target gene operatively connected thereto, wherein the cis-acting element is capable of regulating the expression of the target gene.
[0138] In some embodiments, the cis-acting element may be directly adjacent to the target gene or separated by an inserted nucleotide. In some embodiments, the cis-acting element may be separated from the target gene by an intron.
[0139] In some embodiments, the cis-acting element may be located at the 5' end of the target gene. In some embodiments, the cis-acting element may be located at the 3' end of the target gene. In some embodiments, the expression cassette includes, in a 5' to 3' orientation, a cis-acting element capable of binding to PAX family transcription factors and a target gene operatively linked to the cis-acting element.
[0140] In some embodiments, the relative position of the PAX family transcription factor-binding domain to the target gene can be adjusted, as long as regulation of the target gene is achieved. For example, the distance between the PAX family transcription factor-binding domain and the target gene can range from 20 to 2000 base pairs upstream. Alternatively, the distance can range from 20 to 500 base pairs upstream.
[0141] On the other hand, this application also provides a transcription activator that can enhance the function of the cis-acting element.
[0142] In this application, the expression cassette may further include a gene encoding a transcription activator that enhances the function of the cis-acting element. For example, the transcription activator can promote the transcription of a target gene by enhancing the function of a cis-acting element (such as a promoter). The enhancement of the function of the cis-acting element can be detected by the expression level of the target gene operatively linked to it, and the method for detecting the expression level of the target gene can be known in the art.
[0143] In some embodiments, the transcription activator includes a transcription activation domain. For example, the transcription activation domain can promote the transcription of the target gene by enhancing the function of cis-acting elements (such as promoters).
[0144] In some embodiments, the transcription activator is an artificial transcription activator. For example, the transcription activator may be a fusion polypeptide or fusion protein, which may include a first domain and a second domain.
[0145] In some embodiments, the transcription activator includes a first domain and a second domain, wherein the first domain is capable of binding to the same PAX family transcription factors that bind to the cis-acting element, and the second domain includes a transcription activation domain. In some embodiments, the enhancing effect of the transcription activator on the cis-acting element is specific. For example, this specific enhancement can be achieved by the first domain specifically binding to the same PAX family transcription factors that bind to the cis-acting element.
[0146] In some embodiments, the first domain and the cis-acting element are capable of binding the same PAX family transcription factors. In some embodiments, the first domain and the cis-acting element are capable of binding the same aberrant PAX family transcription factors. In some embodiments, the first domain and the cis-acting element are capable of binding PAX3-FOXO1. In some embodiments, the first domain comprises a lysine-specific demethylase 4B (KDM4B) truncated form that does not contain certain domains of the full-length KDM4B but retains its binding ability to PAX3-FOXO1. In some embodiments, the lysine-specific demethylase 4B (KDM4B) truncated form comprises the amino acid sequence shown in SEQ ID NO: 28.
[0147] The transcription activation domains described in this application can be domains with transcriptional activation functions known in the art. Transcription activation domains typically interact with transcriptional coactivators or transcriptional complexes and promote target gene expression. These domains can be transcription activation domains derived from natural transcription factors (such as VP16) or artificially designed functionally enhanced transcription activation domains. Methods for determining whether a domain is a transcription activation domain are known in the art; for example, point mutation or truncation experiments can be used to identify which regions are central to transcriptional activation function.
[0148] In some embodiments, the transcriptional activation domain includes VPR (VP64-p65-Rta), HEB transcriptional activation domain, VP16 transcriptional activation domain, and / or P300 transcriptional activation domain.
[0149] The VPR described in this application generally refers to a transcription activator composed of three different transcriptional activation domains fused together, specifically comprising: VP64, p65, and Rta. VP64 is derived from the activation domain of the VP16 protein of herpesviruses and is a derivative of VP16, possessing strong transcriptional activation capabilities; p65 is derived from the RelA portion of the p65 subunit of the nuclear factor κB (NF-κB) complex; and Rta is derived from the Rta protein of Kaposi's sarcoma-associated herpesvirus (KSHV). For example, the VPR may contain the amino acid sequence shown in SEQ ID NO: 29.
[0150] HEB (Hematopoietically Expressed Basic Leucine Zipper) typically refers to a bHLH (basic helix-loop-helix) transcription factor. HEB initiates gene transcription by recruiting other transcription factors (such as P300 / CBP) to form dimers, which then bind to the E-box elements of target genes. The HEB transcription activation domain described in this application generally refers to a domain derived from HEB with transcriptional activation function, capable of recruiting transcriptional coactivators and transcription machinery (such as RNA polymerase), thereby enhancing gene transcriptional activity. For example, the HEB transcription activation domain may contain the amino acid sequence shown in SEQ ID NO: 30.
[0151] VP16 (Virion Protein 16) generally refers to a potent transcriptional activator derived from herpes simplex virus (HSV-1), whose transcriptional activation function is typically mediated by its C-terminal transcriptional activation domain. The VP16 transcriptional activation domain described in this application generally refers to a domain derived from VP16 that possesses transcriptional activation function. For example, the VP16 transcriptional activation domain may contain the amino acid sequence shown in SEQ ID NO: 31.
[0152] P300 typically refers to a histone acetyltransferase (HAT) with transcriptional co-activation function, which is widely involved in regulating gene expression. The P300 transcriptional activation domain described in this application generally refers to a domain derived from P300 that has transcriptional activation function. For example, the P300 transcriptional activation domain may contain the amino acid sequence shown in SEQ ID NO: 32.
[0153] In some embodiments, the transcription activator comprises a first domain and a second domain, the first domain comprising a lysine-specific demethylase 4B (KDM4B) truncated variant capable of binding PAX3-FOXO1, and the second domain comprising a VPR, a HEB transcription activation domain, a VP16 transcription activation domain, and / or a P300 transcription activation domain. For example, the transcription activator may comprise the amino acid sequence shown in SEQ ID NO: 33, 35, 37, or 39. For example, the gene encoding the transcription activator may comprise the amino acid sequence shown in SEQ ID NO: 34, 36, 38, or 40.
[0154] In some embodiments, the gene encoding the transcription activator is located at the 5' or 3' end of the target gene. In some embodiments, the expression of the gene encoding the transcription activator is also regulated by the cis-acting element. For example, the gene encoding the transcription activator does not affect the regulation of the target gene expression by the cis-acting element.
[0155] In some embodiments, the cis-acting element, the target gene, and the gene encoding the transcription activator are operatively linked. In some embodiments, the cis-acting element, the target gene, and the gene encoding the transcription activator are directly or indirectly linked. For example, the expression product of the target gene and the transcription activator can be linked by a spliceable linker, thereby ensuring that the expression and function of the target gene are not affected by the transcription activator. For example, there is a sequence encoding a spliceable linker between the target gene and the gene encoding the transcription activator. The spliceable linker can be known in the art, such as a 2A peptide linker.
[0156] In some embodiments, the expression cassette may contain the nucleotide sequences shown in any one of SEQ ID NO: 25-27 and SEQ ID NO: 46-48.
[0157] In this application, the expression cassette may also include other elements, including but not limited to transcription and translation termination signals, translation initiation signals, post-transcriptional regulatory elements, and other elements.
[0158] In this application, the transcription termination signal may include, but is not limited to, polyadenylate signal sequences, such as polyadenylate signal sequences or variants thereof derived from SV40, bovine growth hormone (BGH) gene, rabbit β-globulin (RBG) gene and thymidine kinase gene (TK).
[0159] In this application, the translation initiation sequence may include a Kozak sequence, which may be located between the cis-acting element and the target gene.
[0160] In some embodiments, the expression cassette described herein may sequentially comprise, in a 5' to 3' orientation, the following: the cis-acting element capable of binding to PAX family transcription factors, the target gene, and the polyadenylate signal sequence.
[0161] In some embodiments, the expression cassette described herein may sequentially comprise, in the 5' to 3' direction: the cis-acting element capable of binding to PAX family transcription factors, the Kozak sequence, the target gene, and the polyadenylate signal sequence.
[0162] In some embodiments, the expression cassette described herein may sequentially comprise, in the 5' to 3' direction: the cis-acting element capable of binding to PAX family transcription factors, the target gene, the gene encoding a transcription activator, and the polyadenylate signal sequence.
[0163] In some embodiments, the expression cassette described herein may sequentially comprise, in the 5' to 3' direction: the cis-acting element capable of binding to PAX family transcription factors, the gene encoding a transcription activator, the target gene, and the polyadenylate signal sequence.
[0164] In some embodiments, the expression cassette described herein may sequentially comprise, in the 5' to 3' direction: the cis-acting element capable of binding to PAX family transcription factors, the target gene, a sequence encoding a spliceable linker, the gene encoding a transcription activator, and the polyadenylate signal sequence.
[0165] In some embodiments, the expression cassette described herein may sequentially comprise, in the 5' to 3' direction: the cis-acting element capable of binding to PAX family transcription factors, a Kozak sequence, the target gene, a sequence encoding a spliceable linker, the gene encoding a transcription activator, and the polyadenylate signal sequence.
[0166] Target gene
[0167] In this application, the target gene may encode a polypeptide, protein, or polynucleotide, or may be transcribed into a functional or active polynucleotide, such as an antisense nucleic acid or a repressive oligonucleotide, including antisense DNA and RNA (e.g., miRNA, siRNA, and shRNA).
[0168] In some embodiments, the target gene may encode a target protein, which may include a reporter protein. The reporter protein may be an enzyme, a fluorescent label, a molecule containing a radioactive isotope, or a chemiluminescent or electrochemiluminescent molecule. Exemplary reporter proteins include, but are not limited to, secreted alkaline phosphatase (SEAP), green fluorescent protein (GFP), enhanced green fluorescent protein (eGFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (eYFP), cyan fluorescent protein (CFP), enhanced cyan fluorescent protein (eCFP), blue fluorescent protein (BFP), enhanced blue fluorescent protein (eBFP), MmGFP, dsRed, mCherry, luciferase, and β-galactosidase (lacZ).
[0169] In some embodiments, the target gene may be a therapeutic gene. The therapeutic gene may encode a therapeutic peptide, therapeutic polypeptide, therapeutic protein, or therapeutic polynucleotide. The therapeutic peptide, therapeutic polypeptide, or therapeutic protein may be a peptide, polypeptide, or protein that can be used to restore or replace the function of a defective endogenous peptide, polypeptide, or protein. In some cases, the therapeutic protein or therapeutic polynucleotide may be used to alter the expression level and / or activity of one or more proteins or polynucleotides in host cells. In some embodiments, the target gene may include a gene encoding a cytokine. In some embodiments, the target gene may include a suicide gene.
[0170] In some embodiments, the target gene may be a preventative gene. The preventative gene may encode a preventative peptide, preventative polypeptide, preventative protein, or preventative polynucleotide. The preventative peptide, preventative polypeptide, or preventative protein may be a peptide, polypeptide, or protein that can be used to restore or replace the function of a defective endogenous peptide, polypeptide, or protein. In some cases, the preventative protein or preventative polynucleotide may be used to alter the expression level and / or activity of one or more proteins or polynucleotides in host cells.
[0171] In some embodiments, the target gene may include genes essential for viral replication.
[0172] Modified virus
[0173] On the other hand, this application provides a modified virus. The modified virus provided in this application can be used for tumor treatment and can be referred to as an "oncolytic virus". Oncolytic viruses generally refer to viruses that are designed or modified to selectively infect and kill tumor cells. Oncolytic viruses may have two characteristics: first, they have less impact on normal cells during infection and replication, and are relatively more inclined to infect tumor cells; second, they can induce the death or destruction of tumor cells and may trigger an immune response to eliminate the tumor.
[0174] This application provides a modified virus comprising the cis-acting element and / or the expression cassette described in this application.
[0175] The modified virus described in this application may have the cis-acting element described in this application. In some embodiments, the cis-acting element described in this application may be integrated into the genome of the modified virus.
[0176] In some embodiments, the modified virus may have the expression cassette described in this application. In some embodiments, the modified virus may have the cis-acting element described in this application and a target gene operatively linked to the cis-acting element. In some embodiments, the modified virus may have the cis-acting element described in this application, a target gene operatively linked to the cis-acting element, and a gene encoding a transcription activator described in this application, the transcription activator enhancing the function of the cis-acting element.
[0177] In some embodiments, the modified virus may have a cis-acting element comprising, in a 5' to 3' orientation, a fusion protein containing a PAX family transcription factor capable of binding, and a target gene operatively linked to the cis-acting element. In some embodiments, the modified virus may have a cis-acting element comprising, in a 5' to 3' orientation, a fusion protein containing a PAX family transcription factor capable of binding, a target gene operatively linked to the cis-acting element, and a gene encoding a transcription activator as described in this application, the transcription activator enhancing the function of the cis-acting element.
[0178] This application provides a modified virus having a cis-acting element in the 5' to 3' direction capable of binding to a fusion protein containing a PAX family transcription factor and a target gene operatively linked to said cis-acting element.
[0179] In some embodiments, the cis-acting element in the modified virus capable of binding to a fusion protein containing a PAX family transcription factor may include the cis-acting element provided in this application.
[0180] In some embodiments, the target gene operatively linked to the cis-acting element may include a gene essential for viral replication. Utilizing the virus's tumor-killing ability, by placing a gene essential for viral replication after the cis-acting element described in this application, upon recognition of a fusion protein containing PAX family transcription factors, downstream protein expression is activated, promoting explosive viral proliferation, killing cancer cells, and achieving oncolysis. The modified virus provided in this application not only possesses highly specific replication ability in tumor cells and exhibits excellent killing effects on tumor cells, but also can target and kill a variety of tumor cells.
[0181] In some embodiments, the types of viral replication-essential genes may be one or more, wherein each viral replication-essential gene is regulated by its respective cis-acting element as described in this application.
[0182] Different essential genes for viral replication can be selected for different viruses.
[0183] For example, for herpes simplex virus, the essential genes for viral replication can be selected from envelope glycoprotein L, uracil DNA glycosylase, capsid protein, helicogenase subunit, DNA replication initiation binding helicase, myristic acid derivative protein, deoxyribonuclease, outer serine / threonine protein kinase, DNA packaging terminal enzyme subunit 1, outer protein UL16, DNA packaging protein UL17, capsid triple-stranded subunit 2, major capsid protein, envelope protein UL20, nucleoprotein UL24, DNA packaging protein UL25, capsid maturation protease, capsid protein, envelope glycoprotein B, single-stranded DNA binding protein, DNA polymerase catalytic subunit, nuclear exit layer protein, D, The following proteins are included: NA packaging protein UL32, DNA packaging protein UL33, nuclear export membrane protein, capsid protein, capsid triple subunit 1, ribonucleotide reductase subunit 1, ribonucleotide reductase subunit 2, membrane host shut-off protein, DNA polymerase processing subunit, membrane protein UL45, outer envelope protein VP13 / 14, transactivator protein VP16, outer envelope protein VP22, envelope glycoprotein N, outer envelope protein UL51, helicase-primase primer subunit, envelope glycoprotein K, ICP27, nucleoprotein UL55, nucleoprotein UL56, transcription regulator ICP4, regulatory protein ICP22, envelope glycoprotein D, and membrane protein US8A.
[0184] For example, for adenoviruses, the essential genes for viral replication may be selected from one or more of the following: early protein 1A (E1A), early protein 1B19K, early protein 1B55K, capsid protein Iva2, DNA polymerase, terminal protein precursor pTP, capsid protein 52K, capsid protein precursor pIIIa, pentazoc matrix, core protein pVII, core protein precursor pX, core protein precursor pVI, hexazoc, protease, single-stranded DNA-binding protein, hexamer assembly protein 100K, protein 33K, capsid protein 22K, capsid protein precursor, protein U, fibrin, regulatory protein E4 open reading frame 6 / 7, regulatory protein E4 34K, regulatory protein E4 open reading frame 4, regulatory protein E4 open reading frame 3, regulatory protein E4 open reading frame 2, and regulatory protein E4 open reading frame 1.
[0185] For example, for vaccinia virus, the essential genes for viral replication may be selected from nucleotide reductase small subunit, serine / threonine kinase, DNA-binding viral core protein, polymerase large subunit, RNA polymerase subunit, DNA polymerase, thiol oxidase, presumed DNA-binding viral nucleoprotein, DNA-binding phosphoprotein, viral core cysteine protease, RNA helicase NPH-II, presumed metalloproteinase, transcription elongation factor, glutathione-like protein, RNA polymerase, presumed viral nucleoprotein, late transcription factor VLTF-1, DNA-binding viral nucleoprotein, viral capsid protein, polymerase small subunit, and DNA-dependent RNA polymerase subunit rpo22. DNA-dependent RNA polymerase subunit rpo147, serine / threonine protein phosphatase, IMV heparin-binding surface protein, DNA-dependent RNA polymerase, late transcription factor VLTF-4, DNA topoisomerase type I, large subunit of mRNA occlusive enzyme, viral core protein 107, viral core protein 108, uracil-DNA glycosylase, triphosphatase, 70 kDa small subunit of early gene transcription factor VETF, DNA-dependent RNA polymerase subunit rpo18, nucleoside triphosphate hydrolase-I, small subunit of mRNA occlusive enzyme, rifampicin target, late transcription factor VLTF-2, late transcription factor VLTF-3, disulfide bonds. Formation pathway, core protein 4b precursor p4b, core protein 39kDa, DNA-dependent RNA polymerase subunit rpo19, early gene transcription factor VETF 82kDa large subunit, transcription factor VITF-3 32kDa small subunit, IMV membrane protein 128, core protein 4a precursor P4a, IMV membrane protein 131, phosphorylated IMV membrane protein, IMV membrane protein A17L, DNA helicase, viral DNA polymerase processing factor, IMV membrane protein A21L, palmitoyl protein, intermediate gene transcription factor VITF-3 45kDa large subunit, DNA-dependent RNA polymerase subunit rpo132, dependent The DNA RNA polymerase rpo35, IMV protein A30L, putative ATPase, serine / threonine kinase, EEV mature protein, palmitoylated EEV membrane glycoprotein, IMV surface protein A27L, EEV membrane phosphoglycoprotein, IEV and EEV membrane glycoproteins, EEV membrane glycoprotein, disulfide bond formation pathway protein, putative viral nucleoprotein, IMV membrane protein I2L, poxvirus myristoyl protein, IMV membrane protein L1R, late 16kDa putative membrane protein, putative viral membrane protein H2R, IMV membrane protein A21L, chemokine-binding protein, epidermal growth factor-like protein, and IL-18-binding protein are one or more of these.
[0186] For example, for Coxsackievirus, the essential genes for viral replication may be selected from one or more of protein Vpg, core protein 2A, protein 2B, RNA helicase 2C, protein 3A, protease 3C, reverse transcriptase 3D, capsid protein Vp4, and protein Vp1.
[0187] For example, for measles virus, the essential genes for viral replication may be selected from one or more of nucleoprotein N, phosphoprotein P, matrix protein M, transmembrane glycoprotein F, transmembrane glycoprotein H, and RNA-dependent RNA polymerase L.
[0188] For example, for mumps virus, the essential genes for viral replication may be selected from one or more of nucleoprotein N, phosphoprotein P, fusion protein F, and RNA polymerase L.
[0189] For example, for vesicular stomatitis virus, the essential genes for viral replication may be selected from one or more of glycoprotein G, nucleoprotein N, phosphoprotein P, and RNA polymerase L.
[0190] For example, for poliovirus, the viral replication-essential genes may be selected from one or more of capsid protein VP1, capsid protein VP2, capsid protein VP3, cysteine protease 2A, protein 2B, protein 2C, protein 3A, protein 3B, protease 3C, protein 3D, and RNA-directed RNA polymerase.
[0191] For example, for influenza viruses, the essential genes for viral replication may be selected from one or more of hemagglutinin, neuraminidase, nucleoprotein, membrane protein M1, membrane protein M2, polymerase PA, polymerase PB1-F2 and polymerase PB2.
[0192] In some embodiments, the modified virus may be an adenovirus, and the target gene operatively linked by the cis-acting element may be early protein 1A.
[0193] In some embodiments, to enable the modified virus to specifically proliferate in cells containing fusion proteins comprising PAX family transcription factors, the expression and / or activity of one or more viral replication-essential genes (also referred to as endogenous viral replication-essential genes) in its genome are downregulated. This prevents the modified virus from self-replicating in cells or tissues where PAX family transcription factors are normally expressed, and instead allows it to self-replicate and proliferate only in cells or tissues containing fusion proteins with abnormal PAX family transcription factors. For example, the downregulated viral replication-essential gene does not have the cis-acting element described in this application upstream. For example, the downregulated viral replication-essential gene and the viral replication-essential gene regulated by the cis-acting element are the same viral replication-essential gene, but the downregulated viral replication-essential gene is from the original genome of the virus before modification. In this application, the downregulation may include a reduction or elimination of gene expression of one or more genes.
[0194] In some embodiments, downregulation of genes essential for viral replication may include downregulation using gene editing and / or gene recombination methods. For example, the gene editing may include the use of antisense RNA, siRNA, shRNA, and / or CRISPR / Cas systems.
[0195] In some embodiments, the cis-acting element described in this application and a viral replication-essential gene operatively linked to the cis-acting element can be integrated into the genome of the modified virus. For example, the integration site can be a viral replication-essential gene.
[0196] In some embodiments, the modified virus described in this application is an adenovirus whose genome contains the cis-acting element described in this application and an early protein 1A gene operably linked to the cis-acting element. The cis-acting element and the early protein 1A gene operably linked to the cis-acting element are integrated into the early protein 1A gene site on the genome, and the early protein 1A gene on the genome cannot be expressed, thereby the expression of the early protein 1A gene is regulated by the cis-acting element described in this application.
[0197] In some embodiments, the target gene operatively linked to the cis-acting element that binds to PAX family transcription factors may further include a therapeutic gene. The delivery capability of the virus can be utilized to enable the therapeutic gene to be specifically expressed in tumor cells, thereby achieving a therapeutic effect. For example, the therapeutic gene may include a suicide gene, and the cis-acting element described in this application is operatively linked to the suicide gene. In some embodiments, the cis-acting element described in this application can specifically initiate the expression of the therapeutic gene in cells containing a fusion protein comprising PAX family transcription factors. For example, the cis-acting element described in this application can specifically initiate the expression of a suicide gene in cells containing a fusion protein comprising PAX family transcription factors.
[0198] The modified viruses described in this application may include viruses capable of expressing therapeutic genes and / or viruses capable of delivering said therapeutic genes. For example, the modified viruses may be selected from the group consisting of retroviruses, lentiviruses, adeno-associated viruses, and adenoviruses.
[0199] The modified viruses described in this application may include virus types capable of functioning as oncolytic viruses. For example, the modified viruses may be selected from the group consisting of: adenovirus, vaccinia virus, herpes simplex virus, parvovirus, reovirus, Coxsackie virus, Seneca Valley virus, Semlikie Forest virus, poliovirus, measles virus, Newcastle disease virus, vesicular stomatitis virus, Venezuelan equine encephalitis virus, chicken anemia virus, Malaba virus, and echovirus.
[0200] In some embodiments, the cis-acting element and / or the expression cassette described in this application may be integrated into the genome of the modified virus. In some embodiments, the cis-acting element and / or the expression cassette described in this application may be integrated into any location in the genome of the modified virus, as long as the cis-acting element and / or the expression cassette can perform their function. For example, the cis-acting element and / or the expression cassette may be integrated into gene sites in the viral genome that are to be knocked out or downregulated.
[0201] In some embodiments, the modified virus may have one or more copies of the expression cassette described in this application. When the modified virus has two or more copies of the expression cassette described in this application, the target protein in the expression cassette may be the same or different.
[0202] In some embodiments, the modified virus provided in this application may further include modifications to enhance its tumor specificity, antitumor efficacy, and / or safety. For example, the modified virus provided in this application, in addition to containing viral replication-essential genes operatively linked to the cis-acting elements described in this application, may also express one or more exogenous genes, or knock out and / or downregulate one or more genes.
[0203] In some embodiments, the target gene operatively linked to a cis-acting element that binds to a PAX family transcription factor may include a gene capable of enhancing the antitumor efficacy of the virus. In some embodiments, the target gene may include a target gene that enhances antigen presentation and / or stimulates an immune response. In some embodiments, the target gene may include a gene encoding a cytokine. For example, the cytokine may include interleukins, tumor necrosis factor, interferons, chemokines, lymphokines, and / or growth factors. For example, the gene encoding the cytokine may be derived from a human.
[0204] In some embodiments, the modified virus described in this application may also express cytokines to increase the infiltration of immune cells within the tumor, thereby enhancing the oncolytic effect. For example, the cytokines may include granulocyte-macrophage colony-stimulating factor (GM-CSF). In some embodiments, the target gene may include a gene encoding hyaluronidase. For example, the hyaluronidase gene may include a member of the human hyaluronidase family. For example, the hyaluronidase may include human hyaluronidase PH20.
[0205] In some embodiments, one or more exogenous genes expressed by the modified virus may be operatively linked to a tumor-specific cis-acting element. For example, the tumor-specific cis-acting element may include the cis-acting element described in this application that is capable of binding to PAX family transcription factors. In some embodiments, in the modified virus described in this application, the viral replication-essential gene and the one or more exogenous genes are located in the same expression cassette, i.e., the viral replication-essential gene and the one or more exogenous genes share the same cis-acting element. For example, a nucleotide sequence encoding a linker may be included between the viral replication-essential gene and the one or more exogenous genes. For example, the linker may contain a P2A peptide.
[0206] In some embodiments, in the modified virus described in this application, the viral replication-essential gene and the one or more exogenous genes are located in different expression cassettes, that is, the viral replication-essential gene and the one or more exogenous genes are operatively linked to their respective cis-acting elements.
[0207] For example, the modified virus may contain an expression cassette capable of downregulating genes harmful to normal cells. For example, the modified virus may also contain a gene expressing a tumor-specific antigen. For example, the modified virus may also contain a ligand gene that specifically binds to a tumor surface receptor. In this application, the modified virus may have enhanced ability to target and / or kill tumor cells. For example, compared to unmodified viruses, the modified virus of this application may have enhanced ability to target and / or kill tumor cells. For example, compared to viruses containing other cis-acting elements or other tumor-specific promoters (e.g., cis-acting elements other than those capable of binding to PAX family transcription factors as described in this application), the modified virus of this application may have enhanced ability to target and / or kill tumor cells. For example, compared to viruses whose essential genes for viral replication are regulated by other cis-acting elements or other tumor-specific promoters, the modified virus of this application may have enhanced ability to target and / or kill tumor cells.
[0208] For example, the ability to target tumor cells or the ability to kill tumor cells can be detected and evaluated using methods known in the art. For example, the ability to kill tumor cells can manifest as tumor size stabilization or reduction. For example, the ability to kill tumor cells can manifest as inhibition of tumor cell growth.
[0209] In this application, the modified virus may have reduced virulence. In this application, the modified virus may have no killing ability against normal cells or have reduced killing ability. For example, compared to an unmodified virus, the modified virus of this application may have no killing ability against normal cells or have reduced killing ability. For example, compared to viruses containing other cis-acting elements or other tumor-specific promoters, the modified virus of this application may have no killing ability against normal cells or have reduced killing ability. For example, compared to viruses whose essential genes for viral replication are regulated by other cis-acting elements or other tumor-specific promoters, the modified virus of this application may have no killing ability against normal cells or have reduced killing ability.
[0210] For example, the reduced toxicity and / or the killing ability against normal cells can be detected and evaluated using methods known in the art. For example, toxicity can be determined in vivo in animal models. For example, the body weight of the administered animal in the animal model can be used to illustrate the degree of toxicity. For example, the survival rate of the animal model can be used to illustrate the degree of toxicity.
[0211] Isolated nucleic acid molecules / vectors / cells
[0212] On the other hand, this application provides an isolated nucleic acid molecule capable of encoding the cis-acting element described in this application.
[0213] On the other hand, this application provides an isolated nucleic acid molecule capable of encoding the expression cassette described in this application.
[0214] On the other hand, this application provides an isolated nucleic acid molecule capable of encoding the modified virus described in this application.
[0215] On the other hand, this application provides a carrier containing the nucleic acid molecule described in this application.
[0216] In some embodiments, the vector may be a viral vector. For example, the viral vector may include a DNA viral vector, an RNA viral vector, and / or a retroviral vector. For example, the viral vector may include an integrated viral vector and / or a free viral vector. For example, the vector may include adenovirus vectors, vaccinia virus vectors, herpes simplex virus vectors, parvovirus vectors, reovirus vectors, Coxsackie virus vectors, Seneca Valley virus vectors, Semlikie Forest virus vectors, poliovirus vectors, measles virus vectors, Newcastle disease virus vectors, vesicular stomatitis virus vectors, Venezuelan equine encephalitis virus vectors, chicken anemia virus vectors, Malaba virus vectors, and / or echovirus vectors. For example, the vector may include adeno-associated virus vectors and / or lentiviral vectors.
[0217] In some embodiments, the vector may also be a polynucleotide vector, such as a plasmid, cosmid, or transposon.
[0218] Suitable vectors have been extensively described and are well known in the art. Those skilled in the art will understand that vectors containing the nucleic acid molecules described in this application may also contain other sequences and elements necessary for the replication of the vector in prokaryotic and / or eukaryotic cells. For example, the vectors described in this application may include prokaryotic replicons, i.e., nucleotide sequences having the ability to guide and maintain the replication of the host itself in a prokaryotic host cell (e.g., a bacterial host cell). Such replicons are well known in the art. In some cases, the vector may contain shuttle elements that adapt the vector for replication and integration in prokaryotes and eukaryotes. Furthermore, the vector may also include genes capable of expressing detectable markers (e.g., drug resistance genes). The vector may also have reporter genes, such as genes encoding fluorescent or other detectable proteins.
[0219] This application also provides a cell comprising the isolated nucleic acid molecule and / or the vector. In some cases, the cell can be used to amplify, replicate, package, and / or purify the modified virus, the isolated nucleic acid molecule, or the vector. In other cases, the cell can be used to express a target gene contained in the modified virus, the isolated nucleic acid molecule, or the vector. Therefore, this application also covers methods for expressing a target gene, wherein the modified virus, the isolated nucleic acid molecule, or the vector described in this application can be introduced into a cell, such as a tumor cell. Those skilled in the art will understand the conditions required to introduce the modified virus, the isolated nucleic acid molecule, or the vector into the cell, as well as the conditions that support or promote the expression of the target gene within the cell. Furthermore, the method can be in vivo or in vitro. The cell can include prokaryotic and eukaryotic cells. In some cases, the cell can be a mammalian cell. For example, when the cell is used to package the viral vector, the cell can also be transfected with one or more plasmids or infected with one or more viruses that provide the necessary auxiliary molecules for packaging. In other cases, the cell can stably express one or more auxiliary molecules derived from the genome. Those skilled in the art can select suitable host cells for the amplification, replication, packaging, and / or purification of the vector described in this application. Exemplary mammalian cells may include, but are not limited to, HEK-293 cells.
[0220] This application also provides a method for expressing a target gene, the method comprising introducing the isolated nucleic acid molecule, the vector and / or the modified virus into a host cell, and causing the target gene to be expressed in the host cell.
[0221] This application also provides a method for preparing the modified virus described in this application. In some embodiments, the method may further include the step of isolating the modified virus.
[0222] Pharmaceutical Compositions and Kits
[0223] This application also provides a diagnostic or pharmaceutical composition comprising the modified virus described in this application, the isolated nucleic acid molecule described in this application, the vector described in this application, and / or the cell described in this application.
[0224] The modified viruses described in this application, the isolated nucleic acid molecules described in this application, the vectors described in this application, and / or the cells and other compositions, pharmaceuticals, drugs, and biological agents (proteins) described in this application may be incorporated into the diagnostic and pharmaceutical compositions, for example, pharmaceutically acceptable carriers, diluents, and adjuvants. Carriers, diluents, and adjuvants may include buffers such as phosphates, citrates, or other organic acids; antioxidants such as ascorbic acid; low molecular weight peptides (e.g., fewer than about 10 residues); proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants such as Tween, Pluronics, or polyethylene glycol (PEG). In some cases, a physiologically acceptable carrier is an aqueous pH buffer solution.
[0225] When the composition contains nucleic acid molecules or nucleic acid molecular carriers (e.g., plasmids), the nucleic acid molecules or nucleic acid molecular carriers may exist as “naked DNA” or be prepared in a delivery carrier, such as microparticles or nanoparticles, including liposomes, micelles, lipid particles, ceramic / inorganic particles and virus-like particles.
[0226] This application also provides a kit comprising the modified virus, the isolated nucleic acid molecule, the vector, and / or the host cell. The kit typically also includes a label or instructions that include a description of the components or instructions regarding the use of the components therein, in vitro, or indirectly in vivo. The term "packaging material" refers to the physical structure that contains the components of the kit. The packaging material can sterilely retain the components and may be made of materials commonly used for the above purposes (e.g., paper, corrugated fiber, glass, plastic, foil, ampoules, medicine bottles, tubes, etc.).
[0227] The label or instructions may include identification information, dosage, and clinical pharmacology, pharmacokinetics, and pharmacodynamics of one or more of the components, including the active ingredient's mechanism of action. The label or instructions may include information identifying the manufacturer, batch number, country of origin, production date, and expiration date. The label or instructions may include information on the diseases for which the kit components can be used. The label or instructions may include instructions for clinicians or subjects regarding the use of one or more kit components in methods, uses, or treatment regimens or methods of treatment. Instructions may include dosage, frequency, or duration of the formulation, and an introduction to performing any of the methods, uses, treatment regimens, or prevention or treatment methods described herein.
[0228] The label or instructions may include information about any benefits that the components may provide, such as preventative or therapeutic benefits. The label or instructions may include information about potential adverse side effects, complications, or reactions, such as warnings to subjects or clinicians regarding situations where the use of the particular composition may be unsuitable. Adverse side effects or complications may also occur when a subject is taking, will take, or is currently taking one or more other drugs that may be incompatible with the composition, or when a subject is experiencing, will take, or is undergoing another treatment regimen or treatment that may be incompatible with the composition; therefore, the instructions should include information about these incompatibilities.
[0229] Prevention and / or treatment of diseases
[0230] On the other hand, this application provides the use of the cis-acting element, the expression cassette, the modified virus, the isolated nucleic acid molecule, the vector, and the cell described in this application in the preparation of a medicament for the prevention and / or treatment of diseases.
[0231] On the other hand, this application provides the use of the cis-acting element, the expression cassette, the modified virus, the isolated nucleic acid molecule, the vector, the cell, and / or the pharmaceutical composition described in this application in the treatment of diseases.
[0232] On the other hand, this application provides a method for treating a disease, comprising administering to a subject in need an effective amount of the cis-acting element described in this application, the expression cassette described in this application, the modified virus described in this application, the isolated nucleic acid molecule described in this application, the vector described in this application, the cell described in this application, and / or the pharmaceutical composition described in this application.
[0233] The cis-acting elements, expression cassettes, modified viruses, isolated nucleic acid molecules, vectors, cells, pharmaceutical compositions, and / or medicaments for the prevention and / or treatment of diseases described in this application may be administered in therapeutically effective doses. For example, a therapeutically effective dose may include an amount that, when administered to a subject, effectively prevents or improves symptoms of one or more diseases or conditions, or the development of such diseases or conditions. For example, a therapeutically effective dose may include an amount of a conjugated compound sufficient to cause symptom improvement, such as an amount that treats, cures, prevents, or improves an associated medical condition, or increases the rate of treatment, cure, prevention, or improvement of such conditions. For example, when administering a single active ingredient to an individual, the therapeutically effective dose refers only to that ingredient. For example, when administered in combination, the therapeutically effective dose refers to the combined amount of active ingredients that cause a therapeutic effect, whether administered in combination, sequentially, or simultaneously.
[0234] The cis-acting elements, expression cassettes, modified viruses, isolated nucleic acid molecules, vectors, cells, pharmaceutical compositions, and / or medicaments for the prevention and / or treatment of diseases described in this application can be delivered to subjects in need via any route known in the art. Pharmaceutical carriers and formulations or compositions are also well known in the art. For example, routes of administration may include intravenous, intramuscular, intradermal, subcutaneous, transdermal, mucosal, intratumoral, respiratory, or mucosal routes. The modified viruses, pharmaceutical compositions, and / or medicaments for the prevention and / or treatment of diseases described in this application can be used for administration via a variety of routes.
[0235] The cis-acting elements, expression cassettes, modified viruses, isolated nucleic acid molecules, vectors, cells, pharmaceutical compositions, and / or medicaments for the prevention and / or treatment of diseases described in this application may be administered to subjects in need in combination with at least one pharmaceutical agent. For example, the pharmaceutical agent may include anticancer agents, agonists, antagonists, chemotherapeutic agents, and radioactive agents.
[0236] When the cis-acting element of this application is operatively linked to a suicide gene, the expression cassette described in this application contains a suicide gene, the modified virus described in this application contains a suicide gene, the isolated nucleic acid molecule described in this application, the vector described in this application, and / or the cell described in this application contains a suicide gene, the pharmaceutical composition described in this application may contain a prodrug corresponding to the suicide gene, and the method for preventing and / or treating a disease described in this application may include the step of administering an acceptable amount of the prodrug to a subject. The suicide gene and whether it requires a prodrug are known to those skilled in the art.
[0237] In this application, the prevention and / or treatment not only includes preventing and / or treating disease, but also generally includes preventing the onset of disease, slowing or reversing the progression of disease, preventing or slowing the onset of one or more symptoms associated with the disease, reducing and / or alleviating one or more symptoms associated with the disease, reducing the severity and / or duration of the disease and / or any symptoms associated with it and / or preventing a further increase in the severity of the disease and / or any symptoms associated with it, preventing, reducing or reversing any physiological damage caused by the disease, and any pharmacological effects that are generally beneficial to the patient being treated. For example, the cis-acting elements, expression cassettes, modified viruses, isolated nucleic acid molecules, vectors, cells, pharmaceutical compositions, and / or agents for preventing and / or treating disease described in this application do not need to achieve a complete cure or eradication of any symptoms or manifestations of the disease. As recognized in the relevant art, a drug used as a therapeutic agent may reduce the severity of a given disease state, but does not need to eliminate every manifestation of the disease to be considered a useful therapeutic agent. Similarly, prophylactic administration of treatment constitutes a feasible preventative agent that does not necessarily and completely prevent the onset of the disease. The prevention and / or treatment described in this application may simply reduce the effects of the disease in the subject (e.g., by reducing the number or severity of their symptoms, or by increasing the effectiveness of another treatment, or by producing another beneficial effect), or reduce the likelihood of the disease occurring or worsening.
[0238] The cis-acting elements, expression cassettes, modified viruses, isolated nucleic acid molecules, vectors, cells, pharmaceutical compositions, and / or drugs for the prevention and / or treatment of diseases described in this application can prevent and / or treat tumors.
[0239] For example, the cis-acting element, the expression cassette, the modified virus, the isolated nucleic acid molecule, the vector, the cell, the pharmaceutical composition, and / or the drug for preventing and / or treating diseases described in this application have good therapeutic effects on a variety of tumors.
[0240] In this application, the tumor may include tumors associated with fusion proteins containing PAX family transcription factors. Tumors associated with fusion proteins containing PAX transcription factors can be referenced from: Wachtel M, BW.Unpeaceful roles of mutant PAX proteins in cancer.Semin Cell Dev Biol.2015Aug;44:126-34.doi:10.1016 / j.semcdb.2015.09.011;Wachtel M, BW.PAX3-FOXO1:Zooming in on an "undruggable" target.Semin Cancer Biol.2018Jun;50:115-123.doi:10.1016 / j.semcancer.2017.11.006;Azorsa DO,Khan J.Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies. Mod Pathol. 2021Apr; 34(4):748-757.doi:10.1038 / s41379-020-00719-0; Gu Z, Mullighan CG. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet.2019Feb;51(2):296-307.doi:10.1038 / s41588-018-0315-5;.Najafian A, Zeiger MA.RAS Mutations,and RET / PTC and PAX8 / PPAR-gamma Chromosomal Rearrangements Are Also Prevalent in Benign Thyroid Lesions:Implications Thereof and A Systematic Review.Thyroid.2017Jan;27(1):39-48.doi:10.1089 / thy.2016.0348.
[0241] In some embodiments, the tumor may include tumors associated with the abnormal PAX transcription factor family. For example, the tumor described in this application may include rhabdomyosarcoma, biphenotype sinus sarcoma, B-cell lymphoma, thyroid tumor, etc. For example, the rhabdomyosarcoma may include alveolar rhabdomyosarcoma.
[0242] Without being limited by any theory, the embodiments described below are merely for illustrating the cis-acting elements, modified viruses, expression cassettes, preparation methods, and uses of this application, and are not intended to limit the scope of the invention.
[0243] Example
[0244] Example 1: Construction of Cis-Action Elements
[0245] Analysis of the DNA binding site of the fusion protein PAX3-FOXO1 using the ATAC-seq database revealed that the binding site is centered around CGTGACTAAT, with variable bases at both ends. Based on the domain characteristics of the fusion gene, it is speculated that CGTGACTAAT may be a common binding sequence for the PAX transcription factor family. Therefore, the minimal promoter upstream of the target gene (e.g., the minimal CMV promoter: P...) hCMVmini Pre-insertion binding site (CGTGACTAAT)n, testing cis-acting element (i.e. (CGTGACTAAT)nP) hCMVmini The effectiveness of (CGTGACTAAT)n is shown in the following figure and the figures are tested, and different n values (1-15 copies) are adjusted to optimize the cis-acting element.
[0246] This embodiment illustrates that the cis-acting element in the application can bind to fusion proteins containing the PAX family, such as PAX3-FOXO1, PAX7-FOXO1, PAX3-PPARGC1A, PAX3-MAML3, PAX3-NOCA1, and PAX3-NOCA2. Taking PAX3-FOXO1 as an example, it is verified that the constructed cis-acting element can respond to the activation of these transcription factors and regulate the expression of downstream genes.
[0247] Using SEAP as a reporter gene, a corresponding (CGTGACTAAT)n-SEAP vector was constructed and its expression was validated in HEK293T cells. HEK293T cells were seeded at 6 x 10^4 cells / well in 24-well plates and cultured overnight. PAX3-FOXO1 (10 ng / well), (CGTGACTAAT)n-SEAP (50 ng / well), and pCDNA3.1 (440 ng / well) were mixed and then PEI (1.5 μL / well) was added at a DNA:PEI (1:3) ratio. The mixture was transfected into 24-well plates. The medium was changed after 6 hours, and the supernatant was aspirated and the SEAP value was measured after 48 hours. The results showed that the fusion gene was significantly activated by increasing the n value, and (CGTGACTAAT)15 was the optimal value, exhibiting a high response and extremely low leakage (Figure 1A-Figure 1B). Since fusion proteins such as PAX3-FOXO1 have strong transcriptional activation functions, different concentration gradients of PAX3-FOXO1 fusion protein (1 ng, 5 ng, 10 ng, 20 ng), (CGTGACTAAT)n-SEAP (50 ng / well), and different concentration gradients of pCDNA3.1 (449 ng, 445 ng, 440 ng, 430 ng) were used to test the (CGTGACTAAT) fusion protein constructed in this application. 15- Does the SEAP cis-acting element only respond to low concentrations of the PAX3-FOXO1 transcription factor? After mixing the above transfection system, PEI (1.5 μL / well) was added, and cells were transfected. SEAP expression levels in the cell supernatant were measured after 48 hours. The results showed that the PAX3-FOXO1 fusion protein could still activate the cis-acting element at a low concentration of 1 ng (Figure 1C).
[0248] Using the same experimental method, it was verified that other fusion proteins, such as PAX7-FOXO1, PAX3-MAML3, PAX3-NOCA1, PAX3-NOCA2, and PAX7-PPARAGC1A, could be activated at different concentration gradients (1 ng, 5 ng, 10 ng) (CGTGACTAAT). 15 -SEAP cis-acting element, and wild-type transcription factors PAX3, PAX7, PAX5, PAX8, FOXO1, MAML3, NOCA1, NOCA2, and PPARAGC1A cannot be activated (Figure 1D-1G).
[0249] Example 2: Functional Verification of Cis-Action Elements
[0250] To verify whether the cis-acting element of this application can respond to fusion proteins within cancer cells, the cis-acting element was coupled with green fluorescent protein (EGFP) to construct (CGTGACTAAT). 15 -EGFP, packaged into lentivirus, was used to infect mouse melanoma cell lines B16-PAX3-FOXO1 and B16-PAX7-FOXO1 that were stably transformed by PAX3-FOXO1 and PAX7-FOXO1, as well as the fusion gene-positive cell line RH30 and the fusion gene-negative cell line RD. A positive control lentivirus (P...) was also established. hCMV (-EGFP), after 48 hours, green fluorescence was observed under a fluorescence microscope.
[0251] The results showed that the positive control group confirmed that lentiviruses could infect B16-PAX3-FOXO1, B16-PAX-FOXO1, RH30, and RD cells. In the cis-acting element experimental group, green fluorescent protein (EGFP) was expressed only in B16-PAX3-FOXO1, B16-PAX7-FOXO1, and RH30 cells, while no green fluorescence was observed in RD cells and B16 cells (Figures 2A-2C). This indicates that the cis-acting element designed in this application can specifically respond to fusion proteins in tumor cells.
[0252] To test the compatibility of the cis-acting element described in this application with various therapeutic genes, such as the HSV-TK / GCV suicide gene, the Bax suicide gene, and E1A-mediated oncolytic viruses, a (CGTGACTAAT) was constructed. 15-HSV-TK (its nucleotide sequence is shown in SEQ ID NO: 25), (CGTGACTAAT) 15 -Bax (its nucleotide sequence is shown in SEQ ID NO: 26), (CGTGACTAAT) 15 -E1A (its nucleotide sequence is shown in SEQ ID NO: 27) was packaged into lentiviruses and used to infect RH30 cells. Different killing mechanisms were analyzed and verified. The results showed that the cis-acting element could be operatively linked to the suicide gene HSV-TK / GCV or Bax, and the adenovirus replication key gene E1A to achieve highly efficient killing of RH30 rhabdomyosarcoma cells (Figures 3A-3E).
[0253] To verify the in vivo specificity of the cis-acting element constructed in this application, the cis-acting element was operatively linked to luciferase to construct (CGTGACTAAT). 15 -Fluc (its nucleotide sequence is shown in SEQ ID NO: 24), packaged into an adeno-associated virus vector (AAV) 2 / 9 (System targeting), AAV PG007 (Muscle-targeted)). Administered via tail vein injection (1×10). 11 The study included two groups of luciferase cells (VP / animal), a positive control group (strongly expressing luciferase, PhCMV-Fluc), and a negative control group (PhCMVmini-driven luciferase, PhCMVmini-Fluc). Results showed that similar luciferase signals (none or minimal) were observed in the experimental group as in the negative control group, while strong signals were observed in different organs and tissues in the positive control group (heart, liver, spleen, lung, kidney, brain, small intestine, skeletal muscle) (Figures 4A-4F). These data indicate that the cis-acting element constructed in this application exhibits excellent specificity.
[0254] Example 3: Preparation of Modified Virus
[0255] This application describes the production and acquisition of modified oncolytic adenovirus in HEK-293 cells using the classic AdEasy-1 system, mainly including the following steps (as shown in Figure 5):
[0256] (1) The cis-acting element (CGTGACTAAT) that regulates E1A gene expression in Example 2 15 -E1A) constructs a subclone into the shuttle vector pAdTrack.
[0257] (2) Linearize the shuttle vector plasmid successfully constructed in (1) by digestion with Pme I enzyme, and then dephosphorylate it with alkaline phosphatase to obtain the linearized and dephosphorylated target plasmid fragment containing the cis-acting element of the E1 gene.
[0258] (3) Transform the linearized target plasmid fragment from (2) into the BJ5183 bacterial strain carrying the adenovirus backbone pAdEasy-1 plasmid for direct recombination. Select the recombinant clones on the plate, extract the corresponding plasmids and identify them by Pac I restriction enzyme digestion. The plasmids with two fragments, large (~30Kb) and small (~4Kb), visible by electrophoresis after Pac I digestion are the correct adenovirus recombinants.
[0259] (4) The adenovirus recombinant identified correctly in (3) was amplified in large quantities. The amplified plasmid was linearized by Pac I enzyme digestion and then transfected into HEK-293 cells. The medium was changed 6-8 hours after transfection and cultured for another 7-10 days. During the process, microscopic examination showed that the cells expressed green fluorescence in clusters, resembling meteors, indicating that the initial virus had been generated and replicated in HEK-293 cells. The mixture containing the initial adenovirus was collected after the cells in the dish showed empty plaques or obvious floating and broken cells.
[0260] (5) After repeated freeze-thaw cycles, the adenovirus mixture collected in (4) is centrifuged. The supernatant obtained is the P0 generation adenovirus. After aliquoting, it is stored at -80℃ for subsequent amplification and purification.
[0261] The modified P0 generation oncolytic adenovirus obtained in production needs to be amplified, purified, and detected before it can be used for subsequent efficacy studies. The experimental steps are as follows:
[0262] (1) P0 generation adenovirus was added to a 15cm culture dish newly seeded with HEK-293 cells. After infection, microscopic examination revealed multiple clusters of cells expressing green fluorescence, resembling meteors. The mixture containing adenovirus was collected after numerous empty plaques or obvious cell floating and breakage. After repeated freeze-thaw cycles and centrifugation, the supernatant obtained was P1 generation adenovirus. Similarly, P1 generation adenovirus was used to infect more 15cm dishes of HEK-293 cells to obtain P2 generation adenovirus. This process was repeated for four generations until a large amount of P4 generation adenovirus supernatant was obtained for subsequent in vitro purification and concentration.
[0263] (2) Add 50 mL of virus precipitation solution (20% PEG8000, 2.5 M NaCl) to every 100 mL of P4 generation virus supernatant and incubate overnight at 4 °C to precipitate the virus. Centrifuge the mixture at 12000 rpm for 20 min, discard the supernatant, and resuspend the precipitate completely in 10 mL of CsCl solution with a density of 1.10 g / mL (solvent: 20 mM Tris-HCl, pH 8.0), centrifuge at 7000 rpm for 5 min at 4 °C, and collect the virus suspension.
[0264] (3) Add 2 mL of CsCl solution with a density of 1.40 g / mL (solvent as above) to an ultracentrifuge tube, then add 3 mL of CsCl solution with a density of 1.30 g / mL, and finally add 5 mL of the virus suspension obtained in (2). After centrifuging at 22800 rpm for 2.5 h at 4 °C, collect the virus bands with a density between 1.30 and 1.40 g / mL into a dialysis bag (the dialysis bag needs to be boiled with 10 mM EDTA Na2 for 10 min before use). Dialyze overnight at 4 °C in dialysis buffer (50 g sucrose, 10 mL of 1 M pH 8.0 Tris-HCl solution, 2 mL of 1 M MgCl2 solution to a final volume of 1000 mL) (change the dialysis buffer once in between), collect the virus, aliquot it, and store it at -80 °C.
[0265] (4) Based on experimental requirements, the modified oncolytic adenovirus titer finally obtained in (3) was determined using the VP assay (virus particles), measuring the absorbance of the virus particles at 260 nm. 1 OD value is equivalent to 1.1 × 10⁻⁶. 12 The number of viral particles; PFU assay (plaque forming unit) to determine the number of viral plaques formed in infected monolayer HEK-293 cell cultures.
[0266] Example 4: In vitro and in vivo functional verification of the modified virus
[0267] A novel programmable oncolytic adenovirus (AD) was successfully prepared by packaging a cis-acting element into an adenovirus. P3F-E1A After that, AD P3F-E1A and AD EGFP Infecting fusion protein-positive tumor cell lines B16-PAX3-FOXO1, B16-PAX7-FOXO1, and RH30, and negative cancer cell lines RD and B16, the apoptosis rate was verified using CCK8 assay and crystal violet staining. P3F-E1A The kill specificity. Results showed that adding AD... P3F-E1A Subsequently, the negative cell lines RD and B16 showed no significant cell death, while the positive cell lines B16-PAX3-FOXO1, B16-PAX7FOXO1, and RH30 fusion protein all showed significant cell death (Figures 6A-D), and the killing effect became more significant with increasing MOI (Figure 6B). Crystal violet staining results also showed that AD P3F-E1A It only showed a killing effect on the fusion protein-positive tumor cell line RH30 (Figure 6D).
[0268] To verify AD P3F-E1A In vivo oncolytic effect was assessed by subcutaneously injecting RH30 cells (5 million cells / mouse) into the back of NSG mice to establish RH30 tumor-bearing mouse models. The mice were divided into experimental and control groups. After the tumors reached 100 mm³, the experimental group received intratumoral injection of AD cells.P3F Intratumoral injection of AD in the control group EGFP (Negative control group), injection dose was 6x10 9 / animal, injected once on days 1, 3, and 5, 2 x 10 9 / each, injected once on days 7, 9, 11, and 13, for a total of 7 injections. Tumor size (V = width) was recorded daily. 2 × length / 2) and weight, with the tumor size approaching 2000mm 3 Alternatively, the endpoint could be set at 30 days after drug administration, and tumor analysis would be performed to identify differences between groups (experimental procedure shown in Figure 7A). Results showed that in RH30 tumor-bearing mice, compared to those injected with AD... EGFP AD injection P3F-E1A Afterwards, the growth rate and volume of the tumor on the back of the mouse were significantly higher than those in AD mice. EGFP The control group showed a slower rate of tumor reduction, and the tumor weight was significantly reduced at the treatment endpoint (Figures 7B-7D). Furthermore, intratumoral injection of AD... P3F-E1A Subsequently, the virus remained concentrated within the tumor and did not spread to other organs; no significant difference was observed in the body weight of the mice, indicating that AD... P3F-E1A It has good safety. The above results indicate that AD... P3F-E1A It has good in vitro oncolytic effect and good safety.
[0269] Example 5: Construction of a Cis-Action Element Signal Amplification System
[0270] Based on the cis-acting element (15xP3F) of the fusion protein containing PAX family transcription factors described in this application, a transcriptional activator element (KDM4B(T)-Activation Domain) that recognizes the fusion protein PAX3-FOXO1 is added to construct (CGTGACTAAT). 15 -KDM4B(T)-HEB (named P3F△) (Figure 8A). KDM4B is a protein that directly interacts with the PAX3 / PAX7-FOXO1 fusion protein. KDM4B(T) is a truncated region of KDM4B protein from amino acids 1 to 130, retaining only the functional domain that interacts with the fusion protein (Singh S, Yang J. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma. Sci Transl Med. 2022 Jul 13; 14(653):eabq2096. doi:10.1126 / scitranslmed.abq2096). Using NanoLuc luciferase as a reporter gene, the corresponding (CGTGACTAAT) was constructed. 15-Nanoluc-P2A-KDM4B(T)-VP16,(CGTGACTAAT) 15 -Nanoluc-P2A-KDM4B(T)-VR64,(CGTGACTAAT) 15 -Nanoluc-P2A-VPR(CGTGACTAAT) 15 The Nanoluc-P2A-KDM4B(T)-HEB vector was expressed and validated in HEK293T cells. HEK293T cells were seeded at 6 x 10^4 cells / well in 24-well plates and cultured overnight. PcDNA 3.1 (10 ng / well) was then extracted. (CGTGACTAAT) 15 -Nanoluc-P2A-KDM4B(T)-VP16 (50ng / well), (CGTGACTAAT) 15 -Nanoluc-P2A-KDM4B(T)-VR64(50ng / well),(CGTGACTAAT) 15 -Nanoluc-P2A-VPR(50ng / well)(CGTGACTAAT) 15 Nanoluc-P2A-KDM4B(T)-HEB (50 ng / well) and pCDNA3.1 (440 ng / well) were mixed, and PEI (1.5 μL / well) was added at a DNA:PEI ratio of 1:3. The mixture was then transfected into 24-well plates. The medium was changed after 6 hours, and the supernatant was aspirated and the Nanoluc value was measured after 48 hours. The results showed that the fold increase in system response was significantly enhanced after adding the transcription activator element. The signal amplification system with added KDM4B(T)-HEB exhibited the best P3FΔ effect, while the leakage of the amplification system to wild-type PAX3 was extremely low (Figure 8B).
[0271] The aforementioned cis-acting element containing an amplification system was successfully packaged into an adenovirus to prepare a novel programmable oncolytic adenovirus (oAD). P3F△ After that, to verify oAD P3F△ In vivo oncolytic effects were assessed by subcutaneously injecting RH30 and RD cells (2 million cells / mouse) into the back of NSG mice to establish RH30 and RD tumor-bearing mouse models, respectively. The mice were divided into experimental and control groups. Tumor lysis was measured when the tumor reached 100 mm. 3 Subsequently, the experimental group received intratumoral injection of AD. P3F△ Intratumoral injection of AD in the control group EGFP (Negative control group), injection dose was 6x10 9 / animal, injected once on days 1, 3, and 5, 2 x 10 9 / each, injected once on days 7, 9, 11, and 13, for a total of 7 injections. Tumor size (V = width) was recorded daily. 2× length / 2) and weight, with the tumor size approaching 2000mm 3 Alternatively, the endpoint could be set at 30 days after drug administration, and tumor analysis would be performed to identify differences between groups (experimental procedure shown in Figure 9A). Results showed that in RH30 tumor-bearing mice, compared to those injected with oAD... EGFP inject oAD P3F△ Afterwards, the growth rate and volume of the tumor on the mouse's back were significantly higher than those in oAD. EGFP The control group showed a slower rate of tumor reduction, and the tumor weight was significantly reduced at the treatment endpoint (Figures 9B-9D); while in RD tumor-bearing mice, regardless of the injection of oAD... EGFP or oAD P3F△ Tumors on the backs of mice increased in size over time, and there was no significant difference in tumor size or weight between the two groups at the treatment endpoint (Figures 9E-9G). Furthermore, intratumoral injection of oAD... P3F△ Subsequently, the virus remained concentrated within the tumor and did not spread to other organs; no significant difference was observed in the body weight of the mice, indicating that oAD P3F△ It exhibits good safety (Figure 9H). The above results indicate that oAD... P3F△ It has better in vitro oncolytic effect and good safety.
[0272] Example 6: Comparison of different cis-acting elements
[0273] The sensor described in this application, which responds to PAX family fusion proteins, exhibits better response sensitivity and specificity compared to other sensors capable of binding to or responding to abnormal PAX family fusion protein transcription factors (such as PAX3-FOXO1). Existing research reports that syn-alk-5 is a response sensor used to identify the PAX3-FOXO1 fusion protein. TLB,Knott MML.Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma.Mol Cancer.2022 Oct 13;21(1):199.doi:10.1186 / s12943-022-01641-6.),MYOG(S)-mMEF2(Yoshida H, Yamamoto M.Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells. Transl Oncol. 2021 Feb; 14(2):100997.doi:10.1016 / j.tranon.2020.100997.) et al.
[0274] 6.1 Luciferase was used as a reporter gene, and a corresponding gene (CGTGACTAAT) was constructed. 15 The expression of the SYOG(S)-mMEF2-Nanoluc vector in HEK293T cells was validated. HEK293T cells were seeded at 6 x 10^4 cells / well in 24-well plates and cultured overnight. PAX3-FOXO1 (10 ng / well), (CGTGACTAAT)15-Nanoluc (50 ng / well), SYOG(S)-mMEF2-Nanoluc (50 ng / well), and pCDNA3.1 (440 ng / well) were mixed and then PEI (1.5 μL / well) was added at a DNA:PEI (1:3) ratio. The mixture was transfected into 24-well plates. The medium was changed after 6 hours, and the Nanoluc value was measured after 48 hours. The results showed that among the three cis-acting elements, (CGTGACTAAT)15 had the best response sensitivity, exhibiting high response and extremely low leakage (Figure 10A, where p15Xp3F is the cis-acting element for responding to PAX family fusion proteins described in this application).
[0275] 6.2 luciferase was used as a reporter gene to construct the corresponding syn-alk-5-Nanoluc(P) 5xsyn),MYOG(S)-mMEF2-Nanoluc(P MYOG Ealk-SE-Nanoluc(P) eALK-SE ), vector, and simultaneously construct the commonly used tumor promoter Hetert-Nanoluc (P hTert Survivin-Nanoluc(P) Survivin The expression of PAX3-FOXO1 was validated in HEK293T cells. HEK293T cells were seeded at 6 x 10^4 cells / well in 24-well plates and cultured overnight. Then, PAX3-FOXO1 (10 ng / well) was extracted and expressed in P... P3F△ ,P 5xsyn ,P MYOG ,P eALK-SE ,P hTert ,P Survivin After mixing pCDNA3.1 (50 ng / well) and pCDNA3.1 (440 ng / well), PEI (1.5 μL / well) was added at a DNA:PEI ratio of 1:3. The mixture was then transfected into 24-well plates. The medium was changed after 6 hours, and the supernatant was aspirated and the Nanoluc value was measured after 48 hours. The results showed that, among these responders, P… P3F△ It exhibits optimal response sensitivity, high response, and extremely low leakage (Figure 10B).
[0276] Example 7: Verification of the in vitro and in vivo killing function of the modified virus against patient-derived tumor cells.
[0277] Fish (fluorescence in situ hybridization) was used to detect the expression level of fusion genes in rhabdomyosarcoma samples from patients. Patient samples used in this study were obtained from the patients' tumors. The study was approved by the Ethics Committee of Fudan University Children's Hospital, and patients provided written informed consent (ethics approval number: 2021-280). Tumor tissue from patients was paraffin-embedded to prepare 5 μM thick paraffin sections. Fluorescent probes targeting PAX3 and FOXO1 were designed. PAX3 chromosome breakage analysis was performed using 5'-PAX3-Rhodamine and 3'-PAX3-FITC fluorescent probes, and FOXO1 chromosome breakage analysis was performed using 5'-FOXO1-Rhodamine and 3'-FOXO1-FITC fluorescent probes. Experimental results showed that in a cell count of 200, >20% of the tumor cells showed red-green signal separation of PAX3 (2q35) and FOXO1 (13q14), indicating PAX3 and FOXO1 gene breakage rearrangements (Figure 11A).
[0278] Further in vitro culture of patient-derived tumor cells (ARMS-1) with P3 generation P3 tumor cells was performed, and the expression level of the fusion gene in ARMS-1 was detected. The results showed that PAX3-FOXO1 fusion protein expression was positive in ARMS-1 (Figure 11B). oAD was used. P3F△ and oAD EGFP Infection with ARMS-1 was performed, and oAD was verified using CCK8 apoptosis rate detection technology and crystal violet staining technology. P3F△ The results showed that adding oAD had a destructive effect. P3F△ Subsequently, ARMS-1 cells showed significant mortality, and the killing effect became more pronounced with increasing MOI (Figure 11C). Crystal violet staining results also showed oAD. P3F△ It has a significant killing effect on fusion protein-positive tumor cell lines (Figure 11D).
[0279] Verify oAD P3F△ Oncolytic effect on patient-derived tumor cells (ARMS-1) in vivo. Patient-derived xenograft mice (PDX) were constructed by transplanting fresh tumor tissue (1-3 mm) from patients into immunodeficient mice (NSG). The health status of the mice and tumor growth were monitored regularly. When the tumor reached 50 mm... 3 Subsequently, the mice were divided into an experimental group and a control group. The experimental group received intratumoral injection of oAD. P3F△ Intratumoral injection of oAD in the control group EGFP (Negative control group), injection dose was 2x10 9 / each, once a week for the first 3 weeks, then once every 2 days, for 10 injections. Record the tumor size (V = width) daily. 2 × length / 2) and weight, with the tumor size approaching 2000mm 3 As the endpoint, tumor differences were analyzed among the groups. Results showed that PDX tumor-bearing mice derived from ARMS-1 cells, compared to those injected with oAD... EGFP inject oAD P3F△ Afterwards, the growth rate and volume of the tumor on the mouse's back were significantly higher than those in oAD. EGFP The control group showed a slower rate of decrease (Figure 11F); in addition, intratumoral injection of AD... P3F△ Afterwards, it can significantly improve the survival curve of tumor mice (Figure 11G).
Claims
1. A modified virus having a cis-acting element comprising, in the 5' to 3' direction, a fusion protein containing a PAX family transcription factor and a target gene operatively linked to the cis-acting element, wherein the cis-acting element comprises a PAX family transcription factor-binding domain comprising the nucleotide sequence shown in SEQ ID NO:
1.
2. The modified virus according to claim 1, wherein the domain that binds to the fusion protein containing PAX family transcription factors is capable of binding to the DNA-binding domain of the PAX family transcription factors.
3. The modified virus according to any one of claims 1-2, wherein the cis-acting element comprises a promoter and / or an enhancer.
4. The modified virus according to any one of claims 1-3, wherein the cis-acting element is a promoter, the promoter comprising a domain that binds to PAX family transcription factors and a minimal promoter.
5. The modified virus according to claim 4, wherein the minimal promoter is located at the 3' end of the PAX family transcription factor binding domain.
6. The modified virus according to any one of claims 4-5, wherein the minimum promoter comprises at least one TATA box element.
7. The modified virus according to any one of claims 4-6, wherein the minimal promoter comprises the minimal CMV promoter.
8. The modified virus according to any one of claims 4-7, wherein the minimal promoter comprises the nucleotide sequence shown in SEQ ID NO:
6.
9. The modified virus according to any one of claims 1-8, wherein the domain that binds to PAX family transcription factors comprises the nucleotide sequence shown in any one of SEQ ID NO: 2-5.
10. The modified virus according to any one of claims 1-8, wherein the cis-acting element comprises the nucleotide sequence shown in any one of SEQ ID NO: 7-10.
11. The modified virus according to any one of claims 1-10, wherein the fusion protein comprising PAX family transcription factors includes PAX3-FOXO1, PAX7-FOXO1, PAX3-MAML3, PAX3-NOCA1, PAX3-NOCA2, PAX5-ETV6, PAX5-ELN, PAX7-PPARGC1A, PAX8-GLIS3, and PAX8-PPARG.
12. The modified virus according to any one of claims 1-11, wherein the target gene includes a gene essential for viral replication.
13. The modified virus of claim 12, wherein the expression and / or activity of at least one endogenous viral replication-essential gene is downregulated in the modified virus, so that the virus does not have the ability to self-replicate in cells or tissues in which PAX family transcription factors are normally expressed, and only self-replicates and proliferates in cells or tissues containing fusion proteins comprising PAX family transcription factors.
14. The modified virus according to claim 13, wherein at least one gene essential for endogenous viral replication is downregulated by gene editing and / or gene recombination.
15. The modified virus of claim 14, wherein the gene editing comprises using antisense RNA, siRNA, shRNA and / or a CRISPR / Cas system.
16. The modified virus according to any one of claims 1-15, wherein when the virus is an adenovirus, the target gene is selected from one or more genes essential for viral replication from the group consisting of: early protein 1A, early protein 1B19K, early protein 1B55K, capsid protein Iva2, DNA polymerase, terminal protein precursor pTP, capsid protein 52K, capsid protein precursor pIIIa, pentazoc matrix, core protein pVII, core protein precursor pX, core protein precursor pVI, hexazoc, protease, single-stranded DNA-binding protein, hexamer assembly protein 100K, protein 33K, capsid protein 22K, capsid protein precursor, protein U, fibrin, regulatory protein E4 open reading frame 6 / 7, regulatory protein E4 34K, regulatory protein E4 open reading frame 4, regulatory protein E4 open reading frame 3, regulatory protein E4 open reading frame 2, and regulatory protein E4 open reading frame 1.
17. The modified virus according to any one of claims 1-16, wherein the target gene comprises the early protein 1A gene.
18. The modified virus according to any one of claims 1-17, wherein the target gene comprises the nucleotide sequence shown in SEQ ID NO: 14 or the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO:
13.
19. The modified virus according to any one of claims 1-11, wherein the target gene includes a suicide gene.
20. The modified virus according to claim 19, wherein the target gene comprises the herpes simplex virus thymidine kinase (HSV-TK) gene or the BAX gene.
21. The modified virus according to any one of claims 19-20, wherein the target gene comprises the nucleotide sequence shown in SEQ ID NO: 15 or 17 or the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 16 or 18.
22. The modified virus according to any one of claims 1-21, further comprising a gene encoding a transcription activator that enhances the function of the cis-acting element.
23. The modified virus of claim 22, wherein the transcription activator comprises a transcription activation domain.
24. The modified virus according to claim 23, wherein the transcriptional activation domain comprises VPR (VP64-p65-Rta), HEB transcriptional activation domain, VP16 transcriptional activation domain and / or P300 transcriptional activation domain.
25. The modified virus of claim 24, wherein the VPR comprises the amino acid sequence shown in SEQ ID NO:
29.
26. The modified virus of claim 24, wherein the HEB transcriptional activation domain comprises SEQ ID NO. The amino acid sequence shown in NO:
30.
27. The modified virus of claim 24, wherein the VP16 transcriptional activation domain comprises the amino acid sequence shown in SEQ ID NO:
31.
28. The modified virus according to claim 24, wherein the P300 transcription activation domain comprises the amino acid sequence shown in SEQ ID NO:
32.
29. The modified virus according to any one of claims 22-28, wherein the transcription activator is capable of binding to the same PAX family transcription factors that bind to the cis-acting element.
30. The modified virus according to any one of claims 22-29, wherein the transcription activator comprises a first domain and a second domain, wherein the first domain is capable of binding to the same PAX family transcription factors that bind to the cis-acting element, and the second domain comprises a transcription activation domain.
31. The modified virus of claim 30, wherein the first domain and the cis-acting element are capable of binding PAX3-FOXO1.
32. The modified virus according to any one of claims 30-31, wherein the first domain comprises a lysine-specific demethylase 4B (KDM4B) truncated form.
33. The modified virus according to claim 32, wherein the lysine-specific demethylase 4B The (KDM4B) truncated form contains the amino acid sequence shown in SEQ ID NO:
28.
34. The modified virus according to any one of claims 22-33, wherein the transcription activator comprises the amino acid sequence shown in SEQ ID NO: 33, 35, 37 or 39.
35. The modified virus according to any one of claims 22-34, wherein the gene encoding the transcription activator comprises the nucleotide sequence shown in SEQ ID NO: 34, 36, 38 or 40.
36. The modified virus according to any one of claims 22-35, wherein the gene encoding the transcription activator is located at the 5' or 3' end of the target gene.
37. The modified virus according to any one of claims 1-36, further comprising a polyadenylated nucleotide signal sequence located at the 3' end of the target gene.
38. The modified virus according to any one of claims 1-37, wherein the number of copies of the cis-acting element, which is capable of binding to a fusion protein comprising a PAX family transcription factor in the 5' to 3' direction, and the target gene operatively linked to the cis-acting element, is one or more.
39. The modified virus according to any one of claims 1-38, wherein a cis-acting element comprising, in the 5' to 3' direction, capable of binding to a fusion protein comprising a PAX family transcription factor and a target gene operatively linked to the cis-acting element is integrated into the genome of the modified virus.
40. The modified virus of claim 39, wherein the integration comprises using gene editing and / or gene recombination.
41. The virus according to any one of claims 1-40, wherein the virus is selected from the group consisting of: adenovirus, vaccinia virus, herpes simplex virus, parvovirus, reovirus, Coxsackie virus, Seneca Valley virus, Semliki Forest virus, poliovirus, measles virus, Newcastle disease virus, vesicular stomatitis virus, Venezuelan equine encephalitis virus, chicken anemia virus, Malaba virus, and echovirus.
42. The virus according to any one of claims 1-41, comprising the nucleotide sequence shown in any one of SEQ ID NO: 25-27 and SEQ ID NO: 46-48.
43. An expression cassette comprising, in a 5' to 3' orientation, a cis-acting element capable of binding to a fusion protein containing a PAX family transcription factor and a target gene operatively linked to said cis-acting element, wherein said cis-acting element comprises a PAX family transcription factor-binding domain, said PAX family transcription factor-binding domain comprising the nucleotide sequence shown in SEQ ID NO:
1.
44. The expression cassette of claim 43, wherein the cis-acting element comprises the nucleotide sequence shown in any one of SEQ ID NO: 7-10.
45. The expression cassette according to any one of claims 43-44, wherein the target gene comprises a gene essential for viral replication.
46. The expression cassette according to any one of claims 43-44, wherein the target gene includes a suicide gene.
47. The expression cassette according to any one of claims 43-46, further comprising a gene encoding a transcription activator that enhances the function of the cis-acting element.
48. The expression cassette according to any one of claims 43-47, comprising the nucleotide sequence shown in any one of SEQ ID NO: 25-27 and SEQ ID NO: 46-48.
49. An isolated nucleic acid molecule comprising, in the 5' to 3' direction, a nucleotide sequence encoding a cis-acting element capable of binding to a fusion protein containing a PAX family transcription factor and a target gene nucleotide sequence operatively linked to said cis-acting element, wherein said cis-acting element comprises a PAX family transcription factor-binding domain, said PAX family transcription factor-binding domain comprising the nucleotide sequence shown in SEQ ID NO:
1.
50. An isolated nucleic acid molecule encoding the modified virus according to any one of claims 1-42.
51. An isolated nucleic acid molecule encoding an expression cassette according to any one of claims 43-48.
52. A vector comprising the isolated nucleic acid molecule of any one of claims 49-51.
53. The vector according to claim 52, wherein the vector comprises a viral vector.
54. A cell comprising the modified virus of any one of claims 1-42, the expression cassette of any one of claims 43-48, the isolated nucleic acid molecule of any one of claims 49-51, and / or the vector of any one of claims 52-53.
55. A pharmaceutical composition comprising the modified virus of any one of claims 1-42, the expression cassette of any one of claims 43-48, the isolated nucleic acid molecule of any one of claims 49-51, the vector of any one of claims 52-53 and / or the cell of claim 54, and optionally a pharmaceutically acceptable carrier.
56. The use of the modified virus of any one of claims 1-42, the expression cassette of any one of claims 43-48, the isolated nucleic acid molecule of any one of claims 49-51, the vector of any one of claims 52-53, and / or the cell of claim 54 in the preparation of a medicament, wherein the medicament is for the treatment of tumors.
57. Use of the modified virus of any one of claims 1-42, the expression cassette of any one of claims 43-48, the isolated nucleic acid molecule of any one of claims 49-51, the vector of any one of claims 52-53, the cell of claim 54, and / or the pharmaceutical composition of claim 55 in the treatment of tumors.
58. A method of treating a tumor, comprising administering to a subject in need an effective amount of any of the modified virus of claims 1-42, any of the expression cassettes of claims 43-48, any of the isolated nucleic acid molecules of claims 49-51, any of the vectors of claims 52-53, the cells of claim 54, and / or the pharmaceutical composition of claim 55.
59. The use according to any one of claims 56-57 or the method according to claim 58, wherein the tumor comprises a tumor associated with a fusion protein containing a PAX family transcription factor.
60. The use according to any one of claims 56-57 or the method according to claim 58, wherein the tumor comprises a tumor associated with PAX3-FOXO1, PAX7-FOXO1, PAX3-MAML3, PAX3-NOCA1, PAX3-NOCA2, PAX5-ETV6, PAX5-ELN, PAX7-PPARGC1A, PAX8-GLIS3 and / or PAX8-PPARG.
61. The use according to any one of claims 56-57 or the method according to claim 58, wherein the tumor is selected from one or more of the group consisting of: rhabdomyosarcoma, biphenotypic sinus sarcoma, B-cell lymphoma, and thyroid tumor.
